[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 138
1. Li CP, Chen JS, Chen LT, Yen CJ, Lee KD, Su WP, Lin PC, Lu CH, Tsai HJ, Chao Y: A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Br J Cancer; 2010 Oct 26;103(9):1343-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
  • BACKGROUND: Docetaxel plus cisplatin and 5-fluorouracil has become a new standard for treating advanced gastric cancer.
  • METHODS: Patients with histologically confirmed, locally advanced, or recurrent/metastatic gastric adenocarcinoma without previous chemotherapy were enrolled.
  • CONCLUSION: Concurrent weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin are effective and well tolerated in the treatment of advanced gastric cancer.

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4543-8 [12454110.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):453-8 [15226770.001]
  • [Cites] Cancer Sci. 2004 Aug;95(8):679-84 [15298732.001]
  • [Cites] Cancer. 1978 Mar;41(3):941-7 [638980.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1649-55 [8622084.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Oncology. 1997 Jul-Aug;54(4):275-80 [9216850.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2164-8 [9626217.001]
  • [Cites] Ann Surg. 1951 Jul;134(1):2-7 [14838535.001]
  • [Cites] Gastric Cancer. 2005;8(2):95-102 [15864716.001]
  • [Cites] Eur J Surg Oncol. 2005 Jun;31(5):453-60 [15922879.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] In Vivo. 2005 Sep-Oct;19(5):861-6 [16097439.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5660-7 [16110025.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8389-95 [16293869.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):159-63 [16804524.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1529-32 [16873436.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] Jpn J Clin Oncol. 2007 Jan;37(1):30-7 [17272321.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3217-23 [17664469.001]
  • [Cites] Am J Clin Oncol. 2007 Aug;30(4):346-9 [17762433.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):445-8 [17882656.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jan;63(2):213-8 [18343924.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Gastroenterol. 2000 Jun;30(4):364-71 [10875463.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] Oncology. 2002;63(3):239-47 [12381903.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:13-22 [12401661.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(11):1603-9 [12855268.001]
  • (PMID = 20924378.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin
  • [Other-IDs] NLM/ PMC2990611
  •  go-up   go-down


2. Zins M, Loriau J, Boulay-Coletta I, Julles M, Petit E, Sauvanet A: [Postoperative imaging of the pancreas and duodenum]. J Radiol; 2009 Jul-Aug;90(7-8 Pt 2):918-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT has become the imaging method of reference to detect early postoperative complications and to detect recurrent disease during long-term follow-up.
  • [MeSH-major] Adenocarcinoma / surgery. Duodenum / surgery. Pancreas / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Postoperative Complications / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Contrast Media. Follow-Up Studies. Gastric Bypass. Humans. Male. Middle Aged. Pancreatic Fistula / etiology. Pancreaticojejunostomy. Pancreatitis, Acute Necrotizing / etiology. Radiology, Interventional. Recurrence. Time Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752831.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 57
  •  go-up   go-down


3. Mitomi H, Kishimoto I, Amemiya A, Kaneda G, Adachi K, Shimoda T, Takigawa M, Fukui N, Ohkura Y: Advanced gastric cancer showing long-term complete remission in response to S-1 monotherapy: two case reports. Cases J; 2008;1(1):405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced gastric cancer showing long-term complete remission in response to S-1 monotherapy: two case reports.
  • Case 1 was a 65-year-old male diagnosed with an advanced poorly differentiated adenocarcinoma of the stomach with paraaortic lymph node metastases, which disappeared after S-1 monotherapy.
  • The resected tumor was a medullary type poorly differentiated adenocarcinoma infiltrating the serosa and involving the regional lymph nodes.
  • One year after surgery, endoscopy revealed a recurrent tumor in the jejunal pouch.
  • After the administration of S-1, this recurrent tumor completely disappeared, and she has since maintained CR for 39 months.
  • These cases suggest that a subgroup of patients with advanced gastric cancer may attain CR with S-1 monotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2006;9(2):136-9 [16767370.001]
  • [Cites] Gastric Cancer. 2004;7(4):204-10 [15616768.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1462-6 [1515997.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1117-20 [10572613.001]
  • [Cites] Gastric Cancer. 2003;6(3):197-201 [14520535.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:34-9 [12775018.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:19-23 [12775015.001]
  • [Cites] Gastric Cancer. 2002;5(2):96-101 [12111585.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Jpn J Clin Oncol. 2004 May;34(5):282-6 [15231865.001]
  • (PMID = 19091132.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2615767
  •  go-up   go-down


Advertisement
4. Saito H, Kuroda H, Matsunaga T, Fukuda K, Tatebe S, Tsujitani S, Ikeguchi M: Prognostic indicators in node-negative advanced gastric cancer patients. J Surg Oncol; 2010 Jun 1;101(7):622-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic indicators in node-negative advanced gastric cancer patients.
  • BACKGROUND AND OBJECTIVES: Despite carrying better overall prognoses, some node-negative gastric cancer patients die from recurrent malignancies.
  • Identifying factors associated with disease-specific survival in adequately staged node-negative gastric cancer is important, as these patients are presumably free of microscopic regional metastases and may derive significant benefit from existing or future adjuvant strategies.
  • METHODS: To investigate significant prognostic indicators in node-negative advanced gastric cancer patients, we reviewed 777 advanced gastric cancer patients who had undergone curative gastrectomies.
  • RESULTS: The 5-year survival rate of node-negative advanced gastric cancer patients is 84.9%, which is significantly better than that of patients with lymph node metastasis.
  • The 5-year survival rate of patients with larger tumors (>or=7 cm), poorly differentiated adenocarcinoma, and serosal invasion was 49.1%, which was significantly worse that of patients with fewer or none of these factors.
  • CONCLUSIONS: Tumor size, histology, and the presence of serosal invasion are strong indicators of poor prognosis in node-negative advanced gastric cancer patients.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20461771.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Yamamoto M, Taguchi K, Baba H, Endo K, Kohnoe S, Okamura T, Maehara Y: Peritoneal dissemination of early gastric cancer: report of a case. Surg Today; 2006;36(9):835-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal dissemination of early gastric cancer: report of a case.
  • Recurrence of early gastric cancer is rare, with an incidence of less than 10% in Japan.
  • Using peritoneal lavage cytological examination, we detected tumor cells in the peritoneal cavity of a 73-year-old man undergoing surgery for early gastric cancer.
  • Peritoneal dissemination of early gastric cancer is rare.
  • Thus, we summarized the clinicopathological findings of the total 15 cases of peritoneal dissemination of early gastric cancer documented in the English medical literature, including this case.
  • All of the patients had a tumor size >2 cm, submucosal invasion, differentiated adenocarcinoma, lymph node metastasis, and a shorter disease-free interval (average 33.1 months) than patients with other types of recurrent early gastric cancer, and the involvement of both recurrent lymph nodes and peritoneal dissemination.
  • Based on this analysis, we conclude that patients with early gastric cancer, especially if the tumor is >2 cm with submucosal invasion, should be examined carefully for any form of recurrence.
  • [MeSH-minor] Aged. Disease Progression. Gastric Lavage. Humans. Male. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2001;61(2):102-12 [11528248.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):325-8 [8472141.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):187-91 [9700579.001]
  • [Cites] World J Surg. 1997 May;21(4):434-9 [9143577.001]
  • [Cites] Am J Surg. 1999 Sep;178(3):256-62 [10527450.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):687-92 [8425204.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3174-8 [8242540.001]
  • [Cites] Am J Pathol. 1931 Sep;7(5):423-444.39 [19969977.001]
  • [Cites] Br J Surg. 1992 Jun;79(6):539-42 [1611447.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):436-9 [2340396.001]
  • [Cites] Cancer. 1983 Jan 15;51(2):320-6 [6295599.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1454-9 [7889474.001]
  • [Cites] Surg Gynecol Obstet. 1993 Dec;177(6):593-7 [8266270.001]
  • [Cites] Jpn J Clin Oncol. 1986 Dec;16(4):325-34 [3025477.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):168-72 [7388759.001]
  • (PMID = 16937291.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK: A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol; 2008 Dec;63(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.
  • PURPOSE: Irinotecan (I) and docetaxel (D), each of which has a unique mechanism of action, were recently introduced in the treatment of patients with advanced gastric cancer (AGC).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288477.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Zhang X, Gupta R, Nicastri AD: Bladder adenocarcinoma following gastrocystoplasty. J Pediatr Urol; 2010 Oct;6(5):525-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder adenocarcinoma following gastrocystoplasty.
  • We report the first case of adenocarcinoma arising in the residual native bladder in association with intestinal metaplasia and dysplasia of bladder mucosa 17 years following gastrocystoplasty.
  • Intestinal metaplasia secondary to recurrent urinary infection, chronic inflammation, and some form of irritation may potentiate the development of native bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Urinary Bladder / surgery. Urinary Bladder Neoplasms / etiology. Urologic Surgical Procedures / adverse effects
  • [MeSH-minor] Gastric Mucosa / surgery. Humans. Intestines / pathology. Male. Metaplasia. Young Adult

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20392671.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Kuramochi H, Hayashi K, Uchida K, Nakajima G, Hatori T, Danenberg KD, Danenberg PV, Yamamoto M: High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chemother Pharmacol; 2008 Dec;63(1):85-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty-three recurrent pancreatic cancer patients treated with S-1 were studied.
  • Forty-four colorectal cancer patients and 20 gastric cancer patients treated with S-1 were enrolled as control groups.
  • RESULTS: Intratumoral DPD mRNA expression level was significantly higher in pancreatic cancer than that in colorectal cancer (P = 0.0003; median level, 1.38 vs. 0.44) and gastric cancer (P = 0.0061; 1.38 vs. 0.82).
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Cisplatin / administration & dosage. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Drug Combinations. Female. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Reverse Transcriptase Polymerase Chain Reaction. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics. Tegafur / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18309485.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Drug Combinations; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Suzuki S, Sekikawa K, Fujita S, Abe N, Ishigame T, Okada R, Gonda K, Saito M, Onogi H, Ohki S, Takenoshita S: [A case of recurrent gastric cancer effectively treated by combination chemotherapy of weekly paclitaxel and 5'- DFUR after showing resistance to weekly paclitaxel]. Gan To Kagaku Ryoho; 2006 Mar;33(3):385-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent gastric cancer effectively treated by combination chemotherapy of weekly paclitaxel and 5'- DFUR after showing resistance to weekly paclitaxel].
  • The patient was a 35-year-old woman with lung, bone and lymphnode metastases of gastric cancer after a total gastrectomy two years earlier.
  • This case suggests that combination chemotherapy of weekly paclitaxel and 5'-DFUR might be a promising regimen for recurrent gastric cancer even for patients who show no effect with only paclitaxel administration.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Floxuridine / administration & dosage. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531725.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


10. Masaki K, Nomura M, Inoue Y, Fujita S, Sakao J, Hirota M, Souda S: [A case of peritoneal dissemination of gastric cancer successfully treated by irinotecan combined with cisplatin]. Gan To Kagaku Ryoho; 2005 Jun;32(6):851-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of peritoneal dissemination of gastric cancer successfully treated by irinotecan combined with cisplatin].
  • We report a case of a 59-year-old man with advanced gastric cancer.
  • This case suggests that patients with recurrent peritoneal dissemination of gastric cancer could benefit from CPT-11 with CDDP combination therapy as a second-line or third-line treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15984530.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Ohshima T, Yamada R, Hatori S, Kunisaki C, Makino T, Yamazaki Y, Suda T, Rino Y, Takanashi Y, Imada T: [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
  • In cases with advanced/recurrent gastric cancer undergoing single therapy with TS-1, we retrospectively discussed the antitumor effects and adverse events and considered the clinical utility of TS-1.
  • The subjects consisted of 131 cases with advanced/recurrent gastric cancer who received one or more courses of therapy with TS-1 alone between July 1999 and August 2003.
  • The response rate in all cases was 21% and the median survival time (MST) was 343 days, or 25.3% and 265 days if limited to unresectable and recurrent cases.
  • The response rates were 38.2% for unresectable cases, 16.3% for recurrent cases and 14.6% for curability C cases, and the MSTs were 250 days, 276 days and 419 days, respectively.
  • It was again confirmed that single therapy with TS-1 for advanced/recurrent gastric cancer is an excellent therapy providing both high antitumor effects and safety.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Lymph Nodes / pathology. Neoplasm Recurrence, Local / drug therapy. Oxonic Acid / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912529.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


12. Nashimoto A, Yabusaki H, Nakagawa S: [Evaluation and problems of follow-up surveillance after curative gastric cancer surgery]. Nihon Geka Gakkai Zasshi; 2007 May;108(3):120-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation and problems of follow-up surveillance after curative gastric cancer surgery].
  • An analysis was done of 151 (11.5%) recurrent patients among 1,323 primary gastric cancer patients after curative (R0) resection.
  • There were many peritoneal and remote lymph node recurrences in undifferentiated adenocarcinoma and hematologic recurrence in differentiated adenocarcinoma.
  • Referring to these results, follow-up surveillance programs for early and advanced gastric caner were developed.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Gastrectomy. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Recurrence

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533948.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Carboni F, Lepiane P, Santoro R, Lorusso R, Mancini P, Carlini M, Santoro E: Treatment for isolated loco-regional recurrence of gastric adenocarcinoma: does surgery play a role? World J Gastroenterol; 2005 Nov 28;11(44):7014-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for isolated loco-regional recurrence of gastric adenocarcinoma: does surgery play a role?
  • AIM: To evaluate the role of surgical treatment for isolated loco-regional recurrences of operated gastric adenocarcinoma.
  • METHODS: Among the 837 patients operated for gastric adenocarcinoma between December 1979 and April 2004, 713 (85%) underwent resection with curative intent.
  • A retrospective review of a prospectively collected gastric cancer database was carried out.
  • The recurrence was located in the gastric stump after a STG in three patients, in the esophagojejunal anastomosis after a TG in two patients and in the gastric bed after a TG in one patient.
  • All patients died of recurrent gastric cancer: 2 within 1 year from surgery (8 and 11 mo, respectively), 2 after 16 and 17 mo respectively and 1 after 28 mo from the second operation.
  • CONCLUSION: Surgery plays a very limited role in the treatment for isolated loco-regional recurrence of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Recurrence, Local. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437608.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4717046
  •  go-up   go-down


14. Lim JS, Lee SK, Hyung WJ, Choi JY, Kim MJ, Noh SH, Kim KW: CT colonography for postoperative surveillance after curative gastrectomy in patients with gastric cancer. J Surg Oncol; 2010 Nov 1;102(6):593-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT colonography for postoperative surveillance after curative gastrectomy in patients with gastric cancer.
  • AIM: The purpose was to evaluate the diagnostic role of contrast-enhanced CT colonography (CTC) for follow-up of colorectal cancer screening after curative gastrectomy in patients with gastric adenocarcinomas.
  • MATERIALS AND METHODS: Contrast-enhanced CTC was performed as a substitute for routine follow-up CT for the detection of recurrent lesions in 700 consecutive patients who underwent curative surgery for gastric adenocarcinomas.
  • Clinical and radiologic follow-up with respect to detection of polyp and recurrent lesion was retrospectively assessed.
  • Recurrent lesions of gastric cancer were also detected in eight patients (1.1%).
  • CONCLUSION: In patients who undergo gastrectomy due to gastric adenocarcinoma, contrast-enhanced CTC may offer a unique advantage by allowing simultaneous colorectal cancer screening in addition to its routine role of detecting recurrent lesions during follow-up.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colonography, Computed Tomographic / methods. Colorectal Neoplasms / radiography. Colorectal Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20607754.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


15. Inada S, Tomidokoro T, Fukunari H, Sato T, Hatano T, Nishimura A, Kawauchi Y, Nikkuni K, Shimizu T, Sato T, Yanagi M, Takahashi S, Yoshida H, Sugita M, Hayashi T: Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer. Cancer Chemother Pharmacol; 2009 Jan;63(2):267-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
  • PURPOSE: We aimed to examine the safety and antitumor effects of a combination of S-1 and paclitaxel in patients with unresectable or recurrent gastric cancer in a phase I/II setting.
  • CONCLUSIONS: This phase I/II trial of combination therapy with S-1 and paclitaxel in patients with unresectable or recurrent gastric cancer showed that this regimen has substantial antitumor activity and can be given safely.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379784.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Cansiz H, Yener M, Bozkurt AK, Demir A, Demirkaya A, Sekercioglu N: Surgical treatment of laryngeal tumors with subglottic extension and tracheal tumors with composite nasal septal cartilage graft: technique and outcome. Auris Nasus Larynx; 2008 Sep;35(3):363-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overall complications consisted of subglottic stenosis in one case, and unilateral paralysis of recurrent laryngeal nerve in two cases.
  • The patient with esophagus carcinoma and tracheal invasion was treated by total esophagectomy, gastric pull-up, tracheal resection and CNSCG reconstruction.
  • He died at postoperative 5th day due to mediastinitis as a complication of gastric pull-up.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adult. Aged. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Female. Follow-Up Studies. Humans. Laryngectomy / methods. Magnetic Resonance Imaging. Male. Mesenchymoma / pathology. Mesenchymoma / surgery. Middle Aged. Neoplasm Invasiveness. Papilloma / pathology. Papilloma / surgery. Reconstructive Surgical Procedures / methods. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997246.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


17. Altorjay A: [Modern esophageal surgery and late functional results as equations with several unknowns--Hungarian Academy of Sciences Doctoral Thesis]. Magy Seb; 2008 Oct;61(5):285-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trying to identify various factors being responsible for the above differences, 637 patient's data, who underwent previous oesophago-gastric surgery between 1985-2005, were analyzed.
  • Open surgical procedures are justified even in the new millennium in cases when the patient already underwent previous upper abdominal operations - due to an increased risk of injury because of adhesions - in cases of primarily recurrent paraesophageal hernias after an unsuccessful open and/or laparoscopic reconstruction, as well as in cases of reflux with complications.
  • [MeSH-minor] Adenocarcinoma / physiopathology. Adenocarcinoma / surgery. Adult. Barrett Esophagus / physiopathology. Barrett Esophagus / surgery. Cardia. Esophageal Neoplasms / physiopathology. Esophageal Neoplasms / surgery. Esophageal Perforation / physiopathology. Esophageal Perforation / surgery. Female. Gastroesophageal Reflux / etiology. Humans. Hungary. Male. Middle Aged. Prognosis. Reoperation. Stomach Neoplasms / physiopathology. Stomach Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028662.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


18. Dupeux S, Bricaire L, Bosquet A, Pouchot J, Capron L: [Nonbacterial thrombotic endocarditis and gastric carcinoma]. Rev Med Interne; 2008 Aug;29(8):673-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nonbacterial thrombotic endocarditis and gastric carcinoma].
  • [Transliterated title] Endocardite marastique et adénocarcinome gastrique.
  • We report a 74-year-old woman with acute heart failure and recurrent ischemic strokes as the presenting features of a nonbacterial thrombotic endocarditis complicating a gastric adenocarcinoma.


19. Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T: Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res; 2008 May 15;14(10):3022-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
  • However, the clinical significance of these biomarkers in gastric cancer (GC) remains unclear.
  • EXPERIMENTAL DESIGN: The study group comprised 87 patients who underwent gastrectomy at National Cancer Center Hospital and subsequently received chemotherapy for recurrent or residual tumors.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Gene Expression. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483367.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


20. Kakeji Y, Oki E, Egashira A, Sadanaga N, Takahashi I, Morita M, Emi Y, Maehara Y: Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Oncology; 2009;77(1):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
  • OBJECTIVE: This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer.
  • METHODS: Patients with measurable advanced or recurrent gastric cancer and no prior exposure to the investigational drugs were treated with intravenous docetaxel 35 mg/m(2) on days 1 and 15, and oral S-1 80 mg/m(2)/day on days 1-14 every 4 weeks.
  • CONCLUSION: Biweekly docetaxel combined with S-1 is active in advanced or recurrent gastric cancer, and can be administered with proper management of adverse events in an outpatient clinic.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19556809.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


21. Yoshida T, Yoshikawa T, Tsuburaya A, Kobayashi O, Hasegawa S, Osaragi T, Sairenji M: Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer. Anticancer Res; 2006 Mar-Apr;26(2B):1595-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.
  • BACKGROUND: To confirm the feasibility and efficacy of biweekly irinotecan (CPT-11) plus cisplatin (CDDP) as third-line chemotherapy, the response rate (RR), overall survival and toxicity were evaluated in patients who had been treated with S-1 as a first-line and paclitaxel as a second-line chemotherapy for metastatic gastric cancer.
  • PATIENTS AND METHODS: The eligibility criteria of our study were: i) pathologically-confirmed adenocarcinoma of the stomach, ii) primary non-resectable or recurrent tumors, iii) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or less, iv) age less than 75 years, v) adequate hepatic, renal and bone marrow functions and vi) patients had received S-1 as a first-line and paclitaxel as a second-line chemotherapy and both regimens had failed.
  • CONCLUSION: Biweekly CPT-11 plus CDDP was feasible for S-1- and paclitaxel-refractory metastatic gastric cancer, with moderate activity and favorable toxicity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619577.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


22. Kawauchi S, Kusuda T, Liu XP, Suehiro Y, Kaku T, Mikami Y, Takeshita M, Nakao M, Chochi Y, Sasaki K: Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma?: a comparative molecular-genetic and immunohistochemical study. Am J Surg Pathol; 2008 Dec;32(12):1807-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma?: a comparative molecular-genetic and immunohistochemical study.
  • Although lobular endocervical glandular hyperplasia (LEGH) was originally described as a distinct hyperplastic glandular lesion of the uterine cervix, recent studies have raised a question that LEGH may be a cancerous precursor of minimal deviation adenocarcinoma (MDA) and other mucinous adenocarcinomas (MACs) of the uterine cervix.
  • In the present study, we studied LEGH, MDA, and MAC by using molecular-genetic and immunohistochemical methods for chromosomal imbalance, microsatellite instability, human papillomavirus (HPV) infection, and gastric pyloric-type mucin secretion to clarify their relationship.
  • Comparative genomic hybridization revealed recurrent chromosomal imbalances, that is, gains of chromosome 3q and a loss of 1p, which were common to MDA and MAC, in 3 of 14 LEGHs analyzed (21%).
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


23. Sunose Y, Takeyoshi I, Kawate S, Hamada K, Tsutsumi H, Arakawa K, Tohgo N, Toya H, Ohwada S, Kashiwabara K, Morishita Y: [A recurrent endocrine cell cancer of the stomach showing almost complete remission after chemotherapy for 1 year]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2073-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A recurrent endocrine cell cancer of the stomach showing almost complete remission after chemotherapy for 1 year].
  • We report a recurrent case of gastric endocrine cell cancer that showed a remarkable response to systemic chemotherapy.
  • He was diagnosed with gastric cancer, and underwent a proximal gastrectomy.
  • Then, by approximately 1 year after CDDP and CPT-11 treatments, the recurrent lesions had diminished remarkably and were no longer seen on CT or FDG-PET.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Carcinoma, Small Cell / drug therapy. Liver Neoplasms / drug therapy. Stomach Neoplasms / drug therapy


24. Kim JG, Sohn SK, Song HS, Kwon KY, Do YR, Lee KH, Hyun MS, Ryoo HM, Bae SH, Park KU, Baek JH, Lee WS, Chung JS, Cho GJ, Sohn CH, Jang JS, Chung HY, Yu W: Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol; 2007 Nov;60(6):863-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
  • PURPOSE: Since a weekly administration of paclitaxel has demonstrated a sustained efficacy and more favorable toxicity profile than a 3-weekly administration for various solid tumors, the present study was conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus cisplatin in patients with advanced gastric cancer.
  • PATIENTS AND METHODS: Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 100 mg/m(2) plus cisplatin 35 mg/m(2) on days 1 and 8 based on a 3-week cycle.
  • CONCLUSION: A weekly paclitaxel and cisplatin combination was found to be well-tolerated and effective in patients with advanced gastric cancer.
  • Accordingly, this regimen can be regarded as an important first-line treatment option for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17333192.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Ueda S, Hironaka S, Boku N, Fukutomi A, Yoshino T, Onozawa Y: Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer. Gastric Cancer; 2006;9(3):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
  • BACKGROUND: The combination of irinotecan (CPT-11) and cisplatin (CDDP) is an active regimen for metastatic gastric cancer in the first-line setting.
  • The objective of this retrospective study was to clarify its efficacy and safety in patients with prior chemotherapy for advanced or recurrent gastric cancer.
  • (1) histologically proven gastric cancer with metastatic lesions;.
  • CONCLUSION: A combination of CPT-11 and CDDP may be active and feasible for gastric cancer patients with prior chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2004 Oct;27(5):477-80 [15596914.001]
  • [Cites] Gan To Kagaku Ryoho. 1998 Oct;25(12):1915-24 [9797814.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):641-6 [11857295.001]
  • [Cites] Br J Cancer. 2005 May 23;92 (10 ):1850-4 [15870718.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Jun;21(7):1033-8 [8210254.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5 Suppl 5):16-8 [12109800.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Ann Oncol. 1994 Feb;5(2):189-90 [8186165.001]
  • [Cites] Gan To Kagaku Ryoho. 1999 Mar;26(4):487-96 [10097745.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):319-23 [10458249.001]
  • (PMID = 16952039.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


26. Wilson D, Hiller L, Geh JI: Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol); 2005 Apr;17(2):81-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of second-line chemotherapy for advanced gastric adenocarcinoma.
  • Palliative chemotherapy has been shown to improve survival compared with best supportive care alone in patients with unresectable or recurrent gastric cancer.
  • We review the published data concerning the use of second-line chemotherapy in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Salvage Therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830569.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


27. Suzuki T, Yoshida K, Tanabe K, Hihara J, Ohta K, Hamai Y, Taomoto J, Toge T: [Three advanced gastric cancer patients successfully treated by combination therapy of docetaxel and TS-1]. Gan To Kagaku Ryoho; 2005 Apr;32(4):509-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three advanced gastric cancer patients successfully treated by combination therapy of docetaxel and TS-1].
  • We have experienced three gastric carcinoma cases successfully treated by the combination therapy of docetaxel and TS-1.
  • Case 1: 66-year-old male with advanced gastric cancer invading the pancreas with metastasis to the liver and left neck lymph nodes.
  • Case 2: 50-year-old female with scirrhous gastric carcinoma causing huge amount of malignant ascites.
  • Case 3: 59-year-old male with recurrent gastric cancer of the remnant stomach presenting with obstruction and vessel involvement.
  • Primary and metastatic diseases of these patients were remarkably improved with the combination therapy, indicating that the combination therapy of docetaxel and TS-1 can be a new therapeutic tool for advanced and recurrent gastric cancer patients.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853218.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


28. Yamada K, Sugiyama Y, Seino K, Kobori H, Maruyama M, Shibata S, Kawasaki H, Sasaki M: [A case of a nonresected gastric cancer with peritoneal dissemination maintained on TS-1 and docetaxel combination chemotherapy with good QOL]. Gan To Kagaku Ryoho; 2005 Feb;32(2):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of a nonresected gastric cancer with peritoneal dissemination maintained on TS-1 and docetaxel combination chemotherapy with good QOL].
  • In general, treatment for gastric cancer with peritoneal dissemination or recurrent gastric cancer is outside the scope of surgery.
  • We performed chemotherapy of TS-1 and docetaxel (TXT) in the outpatient clinic on a 72-year-old nonresected gastric cancer patient accompanied by peritoneal dissemination.
  • In conclusion, we reported a treatment method for nonresected gastric cancer, which was treated only on an outpatient basis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Quality of Life. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751637.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


29. Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Ohro S, Tatebe S, Tsujitani S, Ikeguchi M: Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol; 2007 Feb 1;95(2):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters.
  • BACKGROUND AND OBJECTIVES: To improve prognosis of patients with gastric cancer, it is important to detect recurrences at an early stage following surgery.
  • If the site of recurrence can be predicted, recurrent disease can be easier detected at an early stage.
  • We aimed to predict sites of recurrence in patients with advanced gastric carcinoma who underwent curative resection.
  • METHODS: Expressions of vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-ss1, and p53, together with density of microvessels (MVs), and dendritic cell (DC) infiltration were examined by immunohistochemistry to evaluate their relationships with recurrence patterns in patients with advanced gastric carcinoma (n = 92).
  • CONCLUSIONS: Assessment of immunohistochemical parameters can predict sites of recurrence in gastric carcinomas, and thus contributes to improve prognosis.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17262742.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1; 0 / Tumor Suppressor Protein p53; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


30. Klinge U, Ackermann D, Lynen-Jansen P, Mertens PR: The risk to develop a recurrence of a gastric cancer-is it independent of time? Langenbecks Arch Surg; 2008 Mar;393(2):149-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk to develop a recurrence of a gastric cancer-is it independent of time?
  • MATERIALS AND METHODS: To test, whether the incidence for developing a recurrence may be considered as remaining constant over time, we analysed survival data of 446 patients with gastric cancer, operated from 1975-2001 in the Surgical Department of the RWTH Aachen.
  • The (time) constancy of the recurrence incidence encourages the view of recurrent cancer as a chronic problem of a carcinogenic environment.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Neoplasm Recurrence, Local / mortality. Postoperative Complications / mortality. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1727-30 [12702551.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1998 Apr;3(2):201-13 [10819528.001]
  • [Cites] Biochemistry (Mosc). 2005 Sep;70(9):1055-64 [16266279.001]
  • [Cites] Cancer Cell Int. 2005 Mar 02;5(1):5 [15743536.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3035-9 [15833829.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1755-60 [15753371.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1405-10 [16251424.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):571-81 [12496492.001]
  • [Cites] Radiother Oncol. 2001 Dec;61(3):233-46 [11730992.001]
  • [Cites] J Pathol. 1999 Jan;187(1):61-81 [10341707.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):247-55 [15650634.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] J Am Coll Surg. 2005 Oct;201(4):503-10 [16183487.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Theor Biol Med Model. 2006 Oct 17;3:37 [17044918.001]
  • (PMID = 18175141.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


31. Kim SH, Lee GW, Go SI, Cho SH, Kim HJ, Kim HG, Kang JH: A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen. Am J Clin Oncol; 2010 Dec;33(6):572-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
  • OBJECTIVES: A phase II study was carried out to assess the efficacy and toxicity of combination chemotherapy with irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) for the treatment of patients with metastatic or recurring gastric cancer previously treated with fluoropyrimidine-based chemotherapy.
  • METHODS: Eligible patients were those who had metastatic gastric cancer previously treated with a fluoropyrimidine-based chemotherapy regimen or had disease recurrence within 6 months of completing adjuvant fluoropyrimidine-containing chemotherapy.
  • CONCLUSION: Combination chemotherapy with irinotecan, 5-FU, and LV is feasible in gastric cancer patients previously treated with fluoropyrimidine-based chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20042971.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


32. Sharma A, Raina V, Lokeshwar N, Deo SV, Shukla NK, Mohanti BK: Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. Indian J Cancer; 2006 Jan-Mar;43(1):16-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction.
  • BACKGROUND: Unresectable and metastatic gastric cancers carry a poor and dismal prognosis.
  • AIMS: To evaluate safety and efficacy of low-dose cisplatin, etoposide and paclitaxel (CEP) based combination chemotherapy in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction.
  • Twenty-nine had metastatic/inoperable disease and four patients had recurrent disease.
  • CONCLUSION: Combination of low-dose CEP shows good clinical response and an acceptable toxicity profile in advanced or metastatic adenocarcinoma of gastric/gastroesophageal cancers.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagogastric Junction / drug effects. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763357.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Smoot RL, Christein JD, Farnell MB: An innovative option for venous reconstruction after pancreaticoduodenectomy: the left renal vein. J Gastrointest Surg; 2007 Apr;11(4):425-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Pancreatic ductal adenocarcinoma has a high mortality rate with limited treatment options.
  • Mean hospital stay was 14 days and perioperative morbidity included a superficial wound infection, delayed gastric emptying, ascites, and gastrointestinal bleeding in one patient each.
  • Two patients had died during follow-up from recurrent disease at 8.3 and 18.2 months after the operation.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Arch Surg. 2005 Jul;140(7):698-701 [16027337.001]
  • [Cites] Surgery. 2001 Feb;129(2):158-63 [11174708.001]
  • [Cites] Am J Surg. 2003 Aug;186(2):149-53 [12885608.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1089-95 [14675720.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):352-4 [7943594.001]
  • [Cites] J Am Coll Surg. 1995 Apr;180(4):497-8 [7719560.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Hepatogastroenterology. 1997 Nov-Dec;44(18):1619-23 [9427033.001]
  • [Cites] Hepatogastroenterology. 1998 Sep-Oct;45(23):1833-6 [9840158.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):362-5 [15549439.001]
  • [Cites] J Urol. 1975 Mar;113(3):295-8 [1117494.001]
  • (PMID = 17436125.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1852389
  •  go-up   go-down


34. Badgwell B, Cormier JN, Xing Y, Yao J, Bose D, Krishnan S, Pisters P, Feig B, Mansfield P: Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol; 2009 Jan;16(1):42-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attempted salvage resection for recurrent gastric or gastroesophageal cancer.
  • The purpose of this study was to determine the outcome of surgery for patients with recurrent gastric or gastroesophageal cancer.
  • We queried records from 7,459 patients who presented with gastric or gastroesophageal cancer to our institution from 1973 through 2005 to identify those for whom resection of recurrent disease had been attempted.
  • Sixty patients underwent attempted resection for recurrent cancer.
  • In 31 cases (52%), recurrent disease proved unresectable at laparotomy.
  • We conclude that surgical resection of select patients with recurrent gastric or gastroesophageal cancer can result in improved OS but often requires adjacent organ resection or interposition graft placement.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrointestinal Neoplasms / surgery. Neoplasm Recurrence, Local / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2009 Apr;16(4):1074-5; author reply 1076 [19184233.001]
  • (PMID = 18985270.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Dinakar P, Höke A: Paraneoplastic fasciitis-panniculitis syndrome: a neurological point of view. Nat Clin Pract Neurol; 2009 Feb;5(2):113-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 54-year-old woman who had undergone gastrectomy to treat gastric adenocarcinoma 5 years previously and had since been in remission presented to a neuromuscular clinic complaining of stiffening and painful spasms of the legs and abdomen.
  • Repeat pan-CT scans and gastric biopsy confirmed the recurrence of poorly differentiated signet ring gastric adenocarcinoma.
  • DIAGNOSIS: Paraneoplastic fasciitis-panniculitis syndrome associated with the recurrence of poorly differentiated signet ring gastric adenocarcinoma.
  • MANAGEMENT: Chemotherapy of recurrent gastric adenocarcinoma and symptomatic management of painful spasms.

  • Genetic Alliance. consumer health - Panniculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194391.001).
  • [ISSN] 1745-8358
  • [Journal-full-title] Nature clinical practice. Neurology
  • [ISO-abbreviation] Nat Clin Pract Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Abdulkareem FB, Onyekwere CA, Awolola NA, Ajekigbe AT: Clinico-pathological review of malignant gastric tumours in Lagos, Nigeria. Nig Q J Hosp Med; 2010 Apr-Jun;20(2):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathological review of malignant gastric tumours in Lagos, Nigeria.
  • BACKGROUND: Gastric cancer is one of the most common cancers and the 2d most common cause of cancer deaths worldwide.
  • OBJECTIVE: To describe the clinico-pathological features of gastric cancer diagnosed in Lagos and determine the prevalence of H. pylori infection in gastric adenocarcinoma.
  • METHODS: This was a retrospective histopathological study of all gastric cancer seen between 1995 and 2007 in the Morbid Anatomy Department of Lagos University Teaching Hospital as well as two other private histopathology laboratories in Lagos (2002-2007).
  • The blocks and slides of gastric cancer tissue were the materials used for the study.
  • RESULTS: There were 105 cases of gastric cancer (M:F = 2:1, mean age-55.3 years), 81% of which occurred above 45 yrs.
  • There were 95 cases (90%) of adenocarcinomas, 8 (7.6%) mesenchymal tumours with one case each of small cell non-Hodgkin's lymphoma and carcinoid tumour. H. pylori was detected in 15.5% of 45 cases of adenocarcinoma with 36% showing evidence of chronic gastritis in adjacent non cancerous gastric tissue.
  • All patients with clinical data had one or more alarm features; most recurring being abdominal fullness, recurrent vomiting, anorexia and weight loss.
  • CONCLUSION: This study suggests that gastric malignancies are not uncommon in Lagos and often manifest with alarm features which should raise a suspicion particularly in our setting with poor diagnostic endoscopic facilities.
  • [MeSH-major] Adenocarcinoma / pathology. Helicobacter pylori. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21243852.001).
  • [ISSN] 0189-2657
  • [Journal-full-title] Nigerian quarterly journal of hospital medicine
  • [ISO-abbreviation] Nig Q J Hosp Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


38. Rosin D, Goldes Y, Bar Zakai B, Shabtai M, Ayalon A, Zmora O: Laparoscopic subtotal gastrectomy for gastric cancer. JSLS; 2009 Jul-Sep;13(3):318-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic subtotal gastrectomy for gastric cancer.
  • BACKGROUND: The use of laparoscopy in the treatment of gastric malignancy is still controversial.
  • The aim of this study was to review our experience with laparoscopic gastrectomy for gastric malignant tumors amenable to subtotal gastrectomy, and assess the oncologic outcome.
  • RESULTS: Twenty patients were operated on, 18 for gastric adenocarcinoma, one for gastric lymphoma, and one for gastrointestinal stromal tumor.
  • During a mean follow-up of 39 months, 4 patients expired from recurrent and metastatic disease; all had positive lymph nodes.
  • Thus, the application of laparoscopy in the surgical treatment of distal gastric malignancy may be considered; however, further data are needed before this approach can be recommended.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2001 Sep;15(9):928-31 [11605108.001]
  • [Cites] Surg Endosc. 2007 Oct;21(10):1685-9 [17661137.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):933-8 [15194075.001]
  • [Cites] Surg Endosc. 1992 May-Jun;6(3):160 [1386948.001]
  • [Cites] Surg Today. 1999;29(4):389-91 [10211578.001]
  • [Cites] Am J Surg. 2004 Dec;188(6):728-35 [15619491.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):232-7 [15650632.001]
  • [Cites] J Am Coll Surg. 2005 Feb;200(2):191-7 [15664093.001]
  • [Cites] Surgery. 2005 Mar;137(3):317-22 [15746786.001]
  • [Cites] Surg Endosc. 2005 Jul;19(7):933-8 [15920691.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1177-81 [16132317.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):39-45 [16368489.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):500-3 [16437270.001]
  • [Cites] Hepatogastroenterology. 2006 Mar-Apr;53(68):304-8 [16608045.001]
  • [Cites] Ann Surg. 2006 Jun;243(6):738-45; discussion 745-7 [16772777.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Apr;11(2):83-7 [11330389.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):968-71 [12658427.001]
  • (PMID = 19793469.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015960
  •  go-up   go-down


39. Mimae T, Ninomiya M, Sasaki H, Kubo Y, Kojima T, Umeoka T, Takakura N: [A case of recurrent gastric cancer with improvement of obstructive symptoms caused by carcinomatous peritonitis and prolonged survival by chemotherapy with combined use of Paclitaxel and 5-FU]. Gan To Kagaku Ryoho; 2006 Feb;33(2):247-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent gastric cancer with improvement of obstructive symptoms caused by carcinomatous peritonitis and prolonged survival by chemotherapy with combined use of Paclitaxel and 5-FU].
  • A 29-year-old male underwent Cur B surgery including total gastrectomy, pancreaticoduodenectomy, transverse colectomy, and D 2 dissection for scirrhous gastric carcinoma accompanied by duodenal and pancreatic infiltration.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ileus / etiology. Neoplasm Recurrence, Local / drug therapy. Peritonitis / therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484866.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


40. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F, Sakata Y: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer; 2006 Jun 19;94(12):1803-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.
  • Patients with histologically- or cytologically confirmed unresectable or recurrent gastric cancer were eligible.
  • This regimen showed promising activity with moderate toxicities in advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] Gastric Cancer. 2002;5(3):142-7 [12378340.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii31-6 [12810455.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1329-33 [15054450.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1843-51 [15274365.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):380-3 [7914428.001]
  • [Cites] Anticancer Drugs. 1995 Jun;6(3):339-55, 363-8 [7670132.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Med Oncol. 1996 Jun;13(2):87-93 [9013471.001]
  • [Cites] Gan To Kagaku Ryoho. 1998 Oct;25(12):1915-24 [9797814.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Gan To Kagaku Ryoho. 1999 Mar;26(4):487-96 [10097745.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1585-95 [15520058.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):494-501 [15659494.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Gastric Cancer. 2005;8(2):95-102 [15864716.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1644-9 [15856038.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5660-7 [16110025.001]
  • [Cites] Oncol Rep. 2006 Apr;15(4):849-54 [16525670.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2B):1455-62 [16619558.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):783-91 [16557585.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):301-6 [10811496.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1264-70 [12763215.001]
  • (PMID = 16773074.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid
  • [Other-IDs] NLM/ PMC2361339
  •  go-up   go-down


41. Morishita Y, Kasakura Y, Fujii M, Yamagata M, Kochi M, Sato K, Takayama T: [Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report]. Gan To Kagaku Ryoho; 2005 Jun;32(6):847-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report].
  • A 58-year-old man with gastric cancer who had undergone distal gastrectomy on February 8, 2001 was revealed to have anorexia, and was diagnosed with a local recurrence in anastomosis by upper GI examination in August 2003.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15984529.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


42. Macdonald JS: Role of post-operative chemoradiation in resected gastric cancer. J Surg Oncol; 2005 Jun 1;90(3):166-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of post-operative chemoradiation in resected gastric cancer.
  • The curative management of gastric adenocarcinoma depends upon complete resection of the primary tumor.
  • In patients with lymph node metastases in the resected specimen, the relapse and death rates from recurrent cancer are at least 70%-80%.
  • Intergroup study (INT-0116) demonstrated that combined chemoradiation following complete gastric resection improves median time to relapse (30 vs. 19 months, P < 0.0001) and overall survival (35 vs. 28 months, P = 0.01).
  • Future advances in the therapy of resectable gastric cancer may come from studies of pre-operative neoadjuvant chemoradiation and the application of targeted therapies such as growth receptor antagonists and anti-angiogenesis agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • [CommentIn] J Surg Oncol. 2005 Jun 1;90(3):171-3; discussion 173 [15895446.001]
  • (PMID = 15895449.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 17
  •  go-up   go-down


43. Spalding DR, Isla AM, Thompson JN, Williamson RC: Pancreas-sparing distal duodenectomy for infrapapillary neoplasms. Ann R Coll Surg Engl; 2007 Mar;89(2):130-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 9 men and 5 women of median age 56 years, who presented with iron-deficiency anaemia (n = 8), gastric outlet obstruction (n = 4), anaemia and gastric outlet obstruction (n = 1), epigastric pain or mass (1 each).
  • There were 11 malignant neoplasms (adenocarcinoma 5, stromal tumour 4, recurrent seminoma 1, plasmacytoma 1), 2 benign neoplasms (villous adenoma, lipoma) and 1 patient with steroid-induced ulceration.
  • There was one death from gangrenous cholecystitis, one early re-operation for anastomotic bleeding and one late re-operation for delayed gastric emptying secondary to anastomotic stricture, but no pancreatic complications.
  • At a median follow-up of 47 months, three patients had died of recurrent disease while the other 10 were alive and well with no upper gastrointestinal symptoms.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Duodenal Neoplasms / surgery. Pancreas / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Dec;42(12):1533-6 [10613470.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1953-8 [10430376.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(4):414-7 [10664293.001]
  • [Cites] Dig Surg. 2000;17(4):410-2 [11053954.001]
  • [Cites] Ned Tijdschr Geneeskd. 2002 Mar 30;146(13):621-4 [11957383.001]
  • [Cites] Arch Surg. 2002 May;137(5):557-62; discussion 562-3 [11982469.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):82-7 [11986022.001]
  • [Cites] Eur J Surg. 2002;168(2):74-7 [12113274.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1362-3 [12072993.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(3):393-6 [12353155.001]
  • [Cites] Hepatogastroenterology. 2003 May-Jun;50(51):711-3 [12828067.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):727-31 [15143902.001]
  • [Cites] Surg Gynecol Obstet. 1976 Jun;142(6):858-60 [936029.001]
  • [Cites] Am J Proctol Gastroenterol Colon Rectal Surg. 1981 Aug;32(8):18-21, 28 [7027808.001]
  • [Cites] Ann Surg. 1983 Feb;197(2):172-8 [6337568.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2242-50 [4052969.001]
  • [Cites] World J Surg. 1985 Dec;9(6):914-20 [4082613.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):350-4 [3565678.001]
  • [Cites] Br J Surg. 1988 Feb;75(2):184-6 [3349313.001]
  • [Cites] Ann Surg. 1989 May;209(5):593-8; discussion 598-9 [2650645.001]
  • [Cites] Ann Surg. 1989 Oct;210(4):544-54; discussion 554-6 [2679459.001]
  • [Cites] Arch Surg. 1990 Aug;125(8):961-5 [2378560.001]
  • [Cites] Arch Surg. 1992 Aug;127(8):945-9; discussion 949-50 [1353671.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • [Cites] Br J Surg. 1994 Oct;81(10):1472-4 [7820475.001]
  • [Cites] J Surg Oncol. 1995 Jan;58(1):70-3 [7823577.001]
  • [Cites] Surgery. 1995 Mar;117(3):254-9 [7878529.001]
  • [Cites] Ann R Coll Surg Engl. 1994 Nov;76(6):403-4 [7702324.001]
  • [Cites] Jpn J Clin Oncol. 1995 Jun;25(3):109-12 [7596048.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):580-8; discussion 588-92 [7574936.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):62-7 [8554153.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10):835-8 [8884299.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):983-94 [9287993.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] J Gastrointest Surg. 1998 Jan-Feb;2(1):79-87 [9841972.001]
  • [Cites] Dig Surg. 1998;15(5):398-403 [9845621.001]
  • [Cites] Dig Surg. 1999;16(1):22-5 [9949263.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3 [10631358.001]
  • (PMID = 17346405.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1964558
  •  go-up   go-down


44. Nakayama N, Koizumi W, Tanabe S, Sasaki T, Saigenji K: A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). Gastric Cancer; 2006;9(3):185-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
  • BACKGROUND: Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions.
  • We evaluated the efficacy of a low dose of cisplatin combined with methotrexate and 5-fluorouracil (MFP therapy) in diffuse-type advanced gastric cancer.
  • CONCLUSION: MFP therapy is useful for the management of diffuse-type inoperable and recurrent gastric cancer, even in patients with conditions such as pleural effusion, ascites, or lymphangitis carcinomatosa who have a poor prognosis or cannot eat solid food.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Clin Oncol. 1985 Nov;21(11):1321-4 [4076293.001]
  • [Cites] Cancer Treat Rep. 1986 Oct;70(10):1215-7 [3756943.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1263-9 [7999410.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2091-3 [7857709.001]
  • [Cites] Eur J Cancer. 1990 Jan;26(1):63-5 [2138482.001]
  • [Cites] Gan To Kagaku Ryoho. 1992 Jul;19(7):946-53 [1626950.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Cancer Res. 1977 Jan;37(1):327-8 [830420.001]
  • [Cites] Cancer Treat Rep. 1984 Dec;68(12):1497-8 [6542449.001]
  • [Cites] Eur J Surg Oncol. 1987 Jun;13(3):203-6 [3036603.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1277-9 [8067696.001]
  • [Cites] Science. 1979 Sep 14;205(4411):1135-7 [472732.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1695-704 [6161926.001]
  • [Cites] Gastric Cancer. 2000 Aug 4;3(1):19-23 [11984704.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):316-22 [15333683.001]
  • [Cites] Ann Oncol. 1991 Nov-Dec;2(10):751-4 [1801881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Oct;77(10):5663-7 [6160578.001]
  • [Cites] Am J Clin Oncol. 1983 Feb;6(1):35-8 [6682284.001]
  • [Cites] Gan To Kagaku Ryoho. 1987 Aug;14(8):2482-90 [3619460.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):18-22 [6317158.001]
  • [Cites] Cancer Treat Rep. 1985 Apr;69(4):449-50 [4039628.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):52-56 [11957071.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Jun;19(6):717-20 [6683644.001]
  • [Cites] N Engl J Med. 1983 Nov 3;309(18):1094-104 [6353235.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(3):167-72 [8500219.001]
  • [Cites] Surg Oncol. 1992 Jun;1(3):215-21 [1341254.001]
  • [Cites] Gastric Cancer. 2001;4(4):212-8 [11846065.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(1):67-8 [2720894.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] Cancer Treat Rep. 1982 Sep;66(9):1713-7 [7116348.001]
  • [Cites] Cancer Res. 1973 Dec;33(12):3091-5 [4760525.001]
  • [Cites] Lancet. 1986 Feb 1;1(8475):256-8 [2868265.001]
  • (PMID = 16952036.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


45. Nimura H, Mitsumori N, Takahashi N, Kashimura H, Takayama S, Kashiwagi H, Yanaga K: [S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]. Gan To Kagaku Ryoho; 2006 Jun;33 Suppl 1:106-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer].
  • Lentinan (LNT) is a beta-glucan known to have a life-prolonging effect in combination with chemotherapy for patients with unresectable or recurrent gastric cancer.
  • Thus, a multi-center trial of chemo-immunotherapy using S-1 combined with LNT may benefit patients with unresectable or recurrent gastric cancer with acceptable toxicity.
  • S-1+LNT regimen may prolong NC periods in patients with unresectable or recurrent gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897983.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 37339-90-5 / Lentinan; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


46. Matsubara J, Shimada Y, Takashima A, Takahari D, Hirashima Y, Okita NT, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shirao K: A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer. Jpn J Clin Oncol; 2008 Aug;38(8):540-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
  • OBJECTIVE: To determine the dose-limiting toxicity (DLT) and the maximum-tolerated dose (MTD) of combination chemotherapy with leucovorin-modulated weekly bolus 5-fluorouracil (5-FU) and weekly paclitaxel in patients with advanced gastric cancer (GC).
  • METHODS: Chemotherapy-naive patients with histologically proven metastatic or recurrent GC were enrolled.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628316.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


47. Gheorghe C, Iacob R, Dumbrava M, Becheanu G, Ionescu M: Confocal laser endomicroscopy and ultrasound endoscopy during the same endoscopic session for diagnosis and staging of gastric neoplastic lesions. Chirurgia (Bucur); 2009 Jan-Feb;104(1):17-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal laser endomicroscopy and ultrasound endoscopy during the same endoscopic session for diagnosis and staging of gastric neoplastic lesions.
  • We describe for the first time the use of both techniques during the same endoscopic session, in a pilot study, in order to increase the diagnostic yield of histological assessment and provide the staging of the gastric neoplastic lesions thus decreasing the time to therapeutic decision.
  • The indication of CLE/EUS exploration was the presence of a gastric polypoid lesion in 37% of cases, atypical gastric ulcer in 27% of patients, gastric lymphoma 18%, suspicion of gastric cancer recurrence after resection 9% and infiltrating type gastric cancer 9%.
  • Histological assessment after targeted biopsy has established the diagnosis of gastric adenocarcinoma in 55% of cases, gastric lymphoma in 18% of cases, gastric adenoma, gastric GIST and gastric foveolar hyperplasia in 9% of cases respectively.
  • In 2 patients - one case with suspected recurrent gastric cancer after surgery and one case of gastric lymphoma, CLE has indicated normal gastric mucosa.
  • The EUS evaluation showed in one gastric lymphoma patient a lesion interesting the mucosa and submucosa with regional adenopathy and a submucosal lesion with regional adenopathy in the other gastric lymphoma case.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Gastric Mucosa / pathology. Gastric Mucosa / ultrasonography. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388564.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


48. Rabenstein T, May A, Gossner L, Manner H, Pech O, Günter E, Huijmans J, Vieth M, Stolte M, Ell C: Invisible gastric carcinoma detected by random biopsy: long-term results after photodynamic therapy. Endoscopy; 2008 Nov;40(11):899-904
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invisible gastric carcinoma detected by random biopsy: long-term results after photodynamic therapy.
  • BACKGROUND AND STUDY AIMS: Gastric cancer diagnosed from routine gastric biopsies without any evidence of a visible lesion and negative repeated biopsies is an infrequent but serious clinical problem for which gastrectomy has usually been recommended, even if operative specimens do not show cancer either.
  • PATIENTS AND METHODS: 22 patients with invisible gastric cancer (IGC) who presented during a 10-year period (10 men, mean age 56 +/- 15 years) were prospectively included.
  • RESULTS: After a mean follow-up period of 56.2 +/- 27.6 months, three patients had died of causes unrelated to gastric cancer, four had developed mucosal cancer that was successfully treated endoscopically after 4 - 38 months, and the remaining 15 patients remained without evidence of recurrent gastric cancer, lymph-node involvement, or metastases during a follow-up period of 54 +/- 26 months.
  • [MeSH-major] Adenocarcinoma / drug therapy. Carcinoma, Signet Ring Cell / drug therapy. Photochemotherapy. Stomach / pathology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19009482.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


49. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, Kimura Y, Ishida H, Fujitani K, Narahara H, Shimokawa T: Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol; 2008 Mar;38(3):176-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
  • We evaluated the efficacy of this combination in patients with unresectable or recurrent gastric cancer who had been previously treated with S-1.
  • METHODS: Registration was started to enroll 35 patients with advanced/recurrent gastric cancer, who were selected among those with measurable lesions fitting to response evaluation criteria in solid tumors, and with resistant to S-1 treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Floxuridine / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281707.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 039LU44I5M / Floxuridine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


50. Sugishita H, Ishida N, Yoshida M, Sato K, Doi T, Horiuchi A, Watanabe Y: [A case of cervical lymph node recurrence of advanced gastric cancer responding to combination therapy of S-1, CDDP and docetaxel]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1385-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of cervical lymph node recurrence of advanced gastric cancer responding to combination therapy of S-1, CDDP and docetaxel].
  • A 57-year-old man underwent total gastrectomy with D2 lymphadenectomy for advanced gastric cancer.
  • The post operative diagnosis was Stage IIIB (tubular adenocarcinoma, moderately-differentiated type, SE, N2, M0).
  • However, about 14 months later, a gradual left cervical lymph node swelling became evident, with an increase in the level of the tumor marker CA19-9, suggesting recurrence of the gastric cancer.
  • DCS is a potentially effective treatment for recurrent gastric cancer with resistance to S-1.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647733.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


51. Kitajima Y, Yakabe T, Ohtsuka T, Tanaka M, Sato S, Nakafusa Y, Miyazaki K: [Complete response obtained with first-line therapy as S-1, followed by second-line 5'-DFUR plus paclitaxel therapy in a patient with multiple liver and lymph node metastases from gastric cancer]. Gan To Kagaku Ryoho; 2009 May;36(5):851-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response obtained with first-line therapy as S-1, followed by second-line 5'-DFUR plus paclitaxel therapy in a patient with multiple liver and lymph node metastases from gastric cancer].
  • A 82-year-old man with advanced gastric cancer underwent distal gastrectomy in January 2006.
  • The histological diagnosis was poorly-differentiated adenocarcinoma, T2(MP), pN2, sH0, sP0, CY0; fStage III A.
  • The patient has been alive without any recurrent site.
  • Thus 5'-DFUR+paclitaxel as a second-line therapy following S-1 should be recommended for a gastric cancer patient with a recurrent tumor.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461193.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 039LU44I5M / Floxuridine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


52. Hirashima Y, Yamada Y, Matsubara J, Takahari D, Okita N, Takashima A, Kato K, Hamaguchi T, Shirao K, Shimada Y, Taniguchi H, Shimoda T: Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Sci; 2009 Feb;100(2):310-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.
  • However, the clinical significance of these molecules in gastric cancer (GC) remains unclear.
  • Our study group comprised 86 patients who underwent gastrectomy and subsequently received chemotherapy for recurrent or residual tumor.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunoenzyme Techniques. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / metabolism. Intestinal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068081.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


53. Im CK, Rha SY, Jeung HC, Ahn JB, Shin SJ, Noh SH, Roh JK, Chung HC: A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. Am J Clin Oncol; 2010 Feb;33(1):56-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.
  • BACKGROUND: There is no universally confirmed standard chemotherapeutic regimen for advanced gastric cancer (AGC).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19730355.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


54. Takamori H, Kanemitsu K, Tsuji T, Kusano S, Chikamoto A, Okuma T, Iyama K: Metastatic gastric tumor secondary to pancreatic adenocarcinoma. J Gastroenterol; 2005 Feb;40(2):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic gastric tumor secondary to pancreatic adenocarcinoma.
  • Local recurrence, liver metastases, and peritoneal spread are the most common recurrent patterns after curative resection of pancreatic cancer.
  • We report a patient who suffered from gastric metastasis secondary to pancreatic adenocarcinoma 1 year after pancreatectomy.
  • The histological diagnosis was well-differentiated adenocarcinoma of the pancreas, stage IIB; T1N1M0.
  • One month later, she complained of epigastric pain and underwent gastric endoscopy, which revealed a submucosal tumor in the fornix posterior wall.
  • Histological diagnosis of the biopsy specimen was well-differentiated adenocarcinoma, and immunohistochemical studies, using anti-cytokeratin 7 and -20 monoclonal antibodies, were compatible with gastric metastasis from pancreatic carcinoma.
  • A F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) scan revealed a high-uptake lesion, which coincided with the gastric tumor.
  • Histopatholoical examination of the resected specimen revealed submucosal growth of the metastatic cancer (well-differentiated adenocarcinoma).
  • [MeSH-major] Adenocarcinoma / secondary. Pancreatic Neoplasms / pathology. Stomach Neoplasms / secondary
  • [MeSH-minor] CA-19-9 Antigen / blood. Female. Gastric Mucosa / pathology. Gastroscopy. Humans. Immunohistochemistry. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770407.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


55. Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK: Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol; 2008 Feb;61(2):301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
  • PURPOSE: The present study evaluated baseline patient- or tumor-related prognostic factors in patients with advanced gastric adenocarcinoma.
  • PATIENTS AND METHODS: A total of 304 consecutive patients with newly diagnosed metastatic or recurrent gastric cancer treated with one or more cycles of cisplatin-based chemotherapy at the Korea Cancer Center Hospital were enrolled in the current study.
  • CONCLUSION: Five prognostic factors were identified from patients receiving first-line cisplatin-based chemotherapy for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17429626.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


56. Sakamoto T, Yasui H, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamazaki K, Taku K, Machida N, Todaka A, Tomita H, Tsushima T, Taniguchi H, Hamauchi S: Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis. Int J Clin Oncol; 2010 Jun;15(3):287-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
  • BACKGROUND: Efficacy and safety of irinotecan and cisplatin administration every 2 weeks (biweekly regimen) or 4 weeks (4-weekly regimen) in patients with pretreated unresectable or recurrent gastric cancer was retrospectively evaluated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1257-62 [15865075.001]
  • [Cites] Cancer Res. 1989 Aug 15;49(16):4385-9 [2545341.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Jun;21(7):1033-8 [8210254.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2B):1595-8 [16619577.001]
  • [Cites] Gastric Cancer. 2006;9(3):203-7 [16952039.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):319-23 [10458249.001]
  • [Cites] Lancet Oncol. 2009 Nov;10 (11):1063-9 [19818685.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • (PMID = 20217447.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


57. Fatouros M, Roukos DH, Lorenz M, Arampatzis I, Hottentrott C, Encke A, Kappas AM: Impact of spleen preservation in patients with gastric cancer. Anticancer Res; 2005 Jul-Aug;25(4):3023-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of spleen preservation in patients with gastric cancer.
  • BACKGROUND: Resection of the spleen en bloc with the stomach for gastric cancer is still widely performed for a curative resection (R0), but the presence of the spleen may have a favorable effect on recurrence control and survival.
  • The hypothesis that the spleen suppresses tumor growth from minimal residual disease in the critical early postsurgical period and reduces the risk of recurrent disease was tested.
  • PATIENTS AND METHODS: Patients were included who underwent gastrectomy, with or without splenectomy, for gastric adenocarcinoma.
  • CONCLUSION: Our findings indicate that preservation of the spleen may be associated with a reduced risk of early and overall recurrence translated into a better survival in patients receiving curative surgery for gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Spleen / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080561.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


58. Teraishi F, Suzuki T, Nakamoto M, Chikuba A, Nezu M, Shimamura H, Takiue T, Chikuba H: [Marked response to S-1 chemotherapy for para-aortic lymph node metastasis arising from gastric cancer]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1857-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Marked response to S-1 chemotherapy for para-aortic lymph node metastasis arising from gastric cancer].
  • We report a recurrent case of gastric cancer with para-aortic lymph node metastasis that showed a marked response to systemic chemotherapy consisting of S-1 alone.
  • He had a history of distal gastrectomy due to the advanced gastric cancer.
  • Endoscopy revealed a submucosal tumor-like elevation with central ulcer, and the biopsy specimen was poorly-differentiated adenocarcinoma histologically.
  • CT of the abdomen demonstrated a para-aortic lymph node swelling behind the remnant stomach, indicating an unresectable recurrent gastric cancer.
  • The S-1 regime was effective and safe, suggesting that S-1 could be the first-line chemotherapy for recurrent gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Gastric Stump / pathology. Lymph Nodes / pathology. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030024.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


59. Lim JY, Cho JY, Paik YH, Lee DK, Lee SI, Park HJ, Lee SJ, Lee KS, Yoon DS, Choi SH: Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. Oncology; 2007;73(1-2):2-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
  • BACKGROUND: We conducted a phase II study to assess the efficacy and tolerability of docetaxel and epirubicin as salvage chemotherapy in advanced/metastatic gastric cancer patients with documented progression after 5-fluorouracil/platinum-based combination chemotherapy.
  • Twenty-six patients had locally advanced or metastatic disease at the time of diagnosis, and 8 patients had recurrent disease after surgical resection of the primary tumor.
  • CONCLUSION: A combination of chemotherapy with docetaxel and epirubicin showed moderate activity as salvage treatment in advanced/metastatic gastric cancer, especially in patients who had responded to prior chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Salvage Therapy / methods. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18332648.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Platinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


60. Meguro E, Kimura T, Noda Y, Matsumoto Y, Irinoda T, Hayakawa Y, Kobayashi M, Takagane A, Hioki J: [A case of advanced gastric cancer successfully treated with TS-1/CDDP combination chemotherapy, able to maintain CR for more than two years against multiple liver metastases]. Gan To Kagaku Ryoho; 2007 Feb;34(2):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer successfully treated with TS-1/CDDP combination chemotherapy, able to maintain CR for more than two years against multiple liver metastases].
  • INTRODUCTION: In recent years, a high success rate of combination chemotherapy with TS-1/CDDP has been reported against advanced gastric carcinoma.
  • We, this time, experienced a case of advanced hemorrhagic gastric cancer with multiple hepatic metastases for which total gastrectomy was performed, followed by postoperative combination chemotherapy with TS-1/CDDP which culminated in achieving CR for the liver metastases.
  • CASE REPORT: The patient was a 59-year-old woman who was hospitalized for a type IV gastric carcinoma in the upper part of the gastric body.
  • At two years and nine months, the patient is being followed on an outpatient basis without any sign of postoperative recurrent disease.
  • It was inferred that this regimen of TS-1/CDDP is an effective treatment modality not only as preoperative but also postoperative chemotherapy after surgery for advanced gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301537.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


61. Mann CD, Thomasset SC, Johnson NA, Garcea G, Neal CP, Dennison AR, Berry DP: Combined biliary and gastric bypass procedures as effective palliation for unresectable malignant disease. ANZ J Surg; 2009 Jun;79(6):471-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined biliary and gastric bypass procedures as effective palliation for unresectable malignant disease.
  • This study aimed to reappraise the short-term and long-term results of combined biliary/gastric bypass (hepaticojejunostomy and gastrojejunostomy) as palliation for unresectable malignant disease.
  • METHODS: All patients undergoing simultaneous biliary and gastric bypass procedures for unresectable malignant disease between August 2000 and January 2006 were identified and outcomes reviewed.
  • Underlying malignant disease included pancreatic carcinoma (n = 88), duodenal adenocarcinoma (n = 6) and distal cholangiocarcinoma (n = 3).
  • During follow up, two patients developed recurrent jaundice that required transhepatic stenting and two patients developed late gastric outlet obstruction requiring refashioning of the gastrojejunostomy.
  • CONCLUSION: Combined surgical biliary and gastric bypass achieved effective palliation of jaundice and gastric outlet obstruction until death in >95% of patients in this series.
  • [MeSH-major] Biliary Tract Surgical Procedures / methods. Duodenal Neoplasms / surgery. Gastric Bypass / adverse effects. Gastrostomy. Jejunostomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Cholangiocarcinoma / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Palliative Care / methods. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19566872.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


62. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ: A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer; 2008 Aug 19;99(4):584-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
  • This randomised multicentre phase II study was conducted to investigate the activity and safety of two oral fluoropyrimidines, capecitabine or S-1, in elderly patients with advanced gastric cancer (AGC).
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Capecitabine. Drug Combinations. Feasibility Studies. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymphatic Metastasis. Male. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):485-93 [10080589.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2155-61 [15710946.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9113-9 [16361618.001]
  • [Cites] Eur J Cancer. 2006 May;42(7):827-34 [16466913.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jul;36(7):410-7 [16825251.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1821-3 [17488979.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1832-43 [17488981.001]
  • [Cites] Oncologist. 2007 May;12(5):543-54 [17522242.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2118-23 [18445840.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):566-75 [12056707.001]
  • [Cites] Lancet Oncol. 2002 May;3(5):289-97 [12067806.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):1029-30; author reply 1030-1 [12096088.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1383-9 [12663731.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:2-8 [12775012.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2720-6 [15187053.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1344-7 [15319239.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jul;34(7):400-4 [15342667.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • (PMID = 18665164.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2527839
  •  go-up   go-down


63. Nasu K, Maeshiro T, Shida D, Miyamoto S, Inoue S, Umekita N, Ara K: [A case of elder gastric cancer patient who relapsed at the local stomach wall and the regional lymph node at the time of six months after endoscopic submucosal dissection (ESD)]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2067-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of elder gastric cancer patient who relapsed at the local stomach wall and the regional lymph node at the time of six months after endoscopic submucosal dissection (ESD)].
  • Gastroscopy revealed a 15 mm diameter of the type 0-IIa+IIc lesion at the posterior wall to the lesser curvature of the gastric body.
  • And the biopsy of the lesion revealed a moderately differentiated adenocarcinoma (tub2).
  • We explained it to the patient about the necessity of additional gastric resection, but she rejected the operation.
  • Two months after the ESD, gastroscopy revealed no recurrent signs.
  • But six months after the ESD, the local area of the stomach was revealed type 2 advanced gastric cancer, and computed tomography (CT) revealed a lymphoid swelling at the side of lesser curvature.
  • The final pathological diagnosis was T2 (ss) N2H0P0M0, Stage IIIA, based on the Japanese classification of gastric cancer.
  • ESD is a minimally invasive technique and it is safe, convenient, and efficacious from the gastric functional point of view.
  • However, the therapeutic strategies of the early gastric cancer, especially submucosally invasive gastric cancer, must be decided carefully and individually, considering the risk factors and the postoperative quality of life (QOL).
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastroscopy. Lymph Nodes / pathology. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037325.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Lim JY, Cho JY, Oh KJ, Choi SH, Lee SI, Jeung HC: Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. Chemotherapy; 2009;55(4):200-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
  • BACKGROUND: The aim of this clinical study was to evaluate the efficacy of combination chemotherapy of oxaliplatin, leucovorin and continuous-infusion 5-fluorouracil (5-FU) for advanced gastric cancer.
  • METHODS: Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks.
  • CONCLUSION: This study reaffirms the efficacy of oxaliplatin in advanced gastric cancer, but its dose of 100 mg/m(2) remains to be reconsidered in Korean patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Organoplatinum Compounds / administration & dosage. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19451710.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


65. Verschuur EM, Homs MY, Steyerberg EW, Haringsma J, Wahab PJ, Kuipers EJ, Siersema PD: A new esophageal stent design (Niti-S stent) for the prevention of migration: a prospective study in 42 patients. Gastrointest Endosc; 2006 Jan;63(1):134-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between June 2003 and May 2004, 42 patients with malignant dysphagia caused by inoperable carcinoma of the esophagus or gastric cardia were treated with a Niti-S stent.
  • Patients were prospectively followed and data collection focused on recurrent dysphagia, functional outcome, complications, and survival.
  • Five of 42 (12%) patients with a Niti-S stent developed recurrent dysphagia, mainly due to tissue overgrowth (2 of 42; 5%) and stent migration (3 of 42; 7%).
  • CONCLUSIONS: The Niti-S stent provides symptomatic relief of malignant dysphagia and effectively reduces recurrent dysphagia.
  • [MeSH-minor] Adenocarcinoma / therapy. Aged. Carcinoma, Squamous Cell / therapy. Equipment Design. Female. Humans. Male. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377330.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Hou Q, Wu YH, Grabsch H, Zhu Y, Leong SH, Ganesan K, Cross D, Tan LK, Tao J, Gopalakrishnan V, Tang BL, Kon OL, Tan P: Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. Cancer Res; 2008 Jun 15;68(12):4623-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer.
  • Recurrent genomic amplifications and deletions are frequently observed in primary gastric cancers (GC).
  • RAB23 amplifications in primary gastric tumors were confirmed by both fluorescence in situ hybridization and genomic qPCR, and in two independent patient cohorts from Hong Kong and the United Kingdom RAB23 expression was significantly associated with diffuse-type GC (dGC) compared with intestinal-type GC (iGC).
  • These results provide further evidence that dGC and iGC likely represent two molecularly distinct tumor types, and show that investigating focal chromosomal amplifications by combining high-resolution aCGH with expression profiling is a powerful strategy for identifying novel cancer genes in regions of recurrent chromosomal aberration.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Movement. Chromosome Mapping. Chromosomes, Artificial, Bacterial. Cohort Studies. Female. Gene Amplification. Gene Dosage. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genomics. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559507.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.6.1.- / RAB23 protein, human; EC 3.6.1.- / rab GTP-Binding Proteins
  •  go-up   go-down


67. Shimoyama R, Yasui H, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N, Todaka A, Tomita H, Sakamoto T, Tsushima T: Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer; 2009;12(4):206-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
  • BACKGROUND: Although triweekly administration of paclitaxel is approved for gastric cancer in Japan, currently, the drug is often delivered with a weekly schedule because of the equivalent efficacy and lesser toxicity of this dosing schedule as compared with the triweekly administration schedule.
  • Weekly administration of paclitaxel as second-line or first-line chemotherapy for gastric cancer has been reported to yield a response rate of about 20%.
  • Because there has been no report of the efficacy of weekly paclitaxel in the third-line setting, this retrospective study investigated the efficacy and toxicities of weekly paclitaxel used in the third-line setting for the treatment of gastric cancer refractory to all three key drugs, fluorouracil, irinotecan, and cisplatin, used in clinical practice.
  • METHODS: In 85 patients with advanced or recurrent histologically confirmed gastric adenocarcinoma who had failed to respond to prior chemotherapy regimens containing fluorouracil, irinotecan, and cisplatin, paclitaxel (80 mg/m(2)) was administered weekly, three times, for 3 weeks out of 4.
  • CONCLUSION: Weekly paclitaxel administration shows activity against advanced gastric cancer also in the third-line setting.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2002;41(5):418-24 [12442916.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4C):2667-71 [17695430.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 16):128-35 [9007140.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Gastric Cancer. 2006;9(1):14-8 [16557431.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):416-9 [9708646.001]
  • [Cites] Anticancer Drugs. 1998 Apr;9(4):307-10 [9635920.001]
  • [Cites] Surg Today. 2008;38(11):1013-20 [18958560.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1642-9 [18375893.001]
  • [Cites] Ann Oncol. 1994 Feb;5(2):189-90 [8186165.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 May;31(5):759-61 [15170988.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):187-92 [8996141.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):179-81 [10655425.001]
  • [Cites] World J Gastroenterol. 2006 Mar 7;12(9):1412-5 [16552811.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):153-8 [9440737.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Oct;30(10):1529-31 [14584291.001]
  • [Cites] Int J Clin Oncol. 2004 Dec;9 Suppl 3:1-82 [15818867.001]
  • [Cites] Cancer J Sci Am. 1998 Jul-Aug;4(4):269-74 [9689986.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Sep;29(9):1643-6 [12355953.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1133-7 [11583196.001]
  • (PMID = 20047125.001).
  • [ISSN] 1436-3305
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


68. Kim BG, Oh SY, Kwon HC, Lee S, Lee DM, Kim SG, Kim DK, Jang JS, Kim MC, Kim SH, Kim HJ: A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer. Am J Clin Oncol; 2010 Jun;33(3):246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
  • BACKGROUND: To determine the activity and toxicities of a low-dose leucovorin plus 5-fluorouracil (5-FU) regimen, combined with irinotecan and administered every 2 weeks (modified FOLFIRI), as a first-line therapy for patients with advanced gastric cancer.
  • CONCLUSIONS: The modified FOLFIRI regimen-lowering of irinotecan and LV doses-is a safe and feasible regimen as a first-line therapy for patients with recurrent or metastatic gastric cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Fluorouracil / therapeutic use. Leucovorin / therapeutic use. Salvage Therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770628.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


69. Ishikawa M, Kitayama J, Fujii S, Ishigami H, Kaizaki S, Nagawa H: Recurrent intramucosal gastric carcinoma with extensive invasion to duodenal mucosa after endoscopic mucosal resection: a case report. Am Surg; 2005 Apr;71(4):366-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent intramucosal gastric carcinoma with extensive invasion to duodenal mucosa after endoscopic mucosal resection: a case report.
  • The occurrence of early gastric carcinoma with invasion to the duodenum is supposed to be very low, although advanced cancers arising in the antrum can often invade the duodenal area.
  • Generally, malignant invasion of the duodenum is difficult to diagnose preoperatively, as spread of gastric cancer to the duodenum is often infiltrative and invades through the submucosal or subserosal layer.
  • We report an unusual case of an intramucosal gastric carcinoma with extensive duodenal invasion that was preoperatively diagnosed by endoscopy.
  • [MeSH-major] Adenocarcinoma / pathology. Duodenal Neoplasms / pathology. Endoscopy, Gastrointestinal. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Follow-Up Studies. Gastrectomy. Gastric Mucosa / pathology. Humans. Laser Coagulation. Male. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943416.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Tsushima T, Hironaka S, Boku N, Machida N, Yamazaki K, Yasui H, Taku K, Fukutomi A, Onozawa Y: Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer. Gastric Cancer; 2010 Nov;13(4):245-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
  • BACKGROUND: Although S-1 is effective against advanced gastric cancer (AGC), its efficacy in elderly patients has not yet been investigated sufficiently.
  • METHODS: We conducted a retrospective review of the data of 153 patients with unresectable/recurrent gastric adenocarcinoma who received S-1 monotherapy as first-line chemotherapy at our institution.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1987 Jul;78(7):748-55 [3114201.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):541-8 [1548519.001]
  • [Cites] Postgrad Med J. 2005 Jul;81(957):419-24 [15998815.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 May;65(6):1093-9 [19727730.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] J Am Geriatr Soc. 1985 Apr;33(4):278-85 [3989190.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] Br J Cancer. 2008 Aug 19;99(4):584-90 [18665164.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):827-31 [2016625.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1832-43 [17488981.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] JAMA. 1985 Apr 12;253(14):2061-7 [2579257.001]
  • [Cites] Curr Treat Options Oncol. 2008 Jun;9(2-3):191-203 [18663583.001]
  • [Cites] Gastric Cancer. 2005;8(1):6-11 [15747168.001]
  • [Cites] Lancet Oncol. 2002 May;3(5):289-97 [12067806.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2687-93 [7989945.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):517-22 [18256586.001]
  • [Cites] Ann Oncol. 1994 Feb;5(2):189-90 [8186165.001]
  • [Cites] Salud Publica Mex. 1997 Jul-Aug;39(4):318-30 [9337564.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):412-6 [8113849.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2000-5 [10473078.001]
  • [Cites] Lancet Oncol. 2009 Nov;10 (11):1063-9 [19818685.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • (PMID = 21128060.001).
  • [ISSN] 1436-3305
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


71. Park SS, Kim CS, Mok YJ, Kim SJ, Kim HI: Gastric cancer confined to the muscularis propria: a possible candidate for laparoscopic surgery or adjuvant therapy. Scand J Gastroenterol; 2005 Apr;40(4):450-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer confined to the muscularis propria: a possible candidate for laparoscopic surgery or adjuvant therapy.
  • OBJECTIVE: Gastric cancer confined to the muscularis propria (mp) has a favorable prognosis, but still belongs to the advanced category.
  • To clarify the therapeutic strategy, the clinicopathological characteristics were investigated, and the risk factors, of this intermediate-stage gastric cancer, evaluated.
  • MATERIAL AND METHODS: A total of 155 patients who underwent curative resection for primary gastric cancer between 1993 and 2001 were diagnosed with mp cancer.
  • The patients were divided into recurrent and non-recurrent groups and analyzed clinicopathologically.
  • Hematogenous metastasis accounted for 37% of the recurrent patterns, and the liver (83.3%) was the most common organ.
  • The 5-year survival rate of all mp cancer patients was 80.9%, but that of patients with recurrent disease was 19.2%.
  • On the other hand, patients with mp cancer without lymph node involvement have an excellent prognosis and could be candidates for laparoscopic gastric surgery.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Laparoscopy. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028440.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


72. Ohi S, Takahashi N, Hashimoto H, Tachibana T, Hirabayashi T, Sugiyama K, Yanaga K, Ishikawa H: Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach. Hum Cell; 2007 May;20(2):52-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach.
  • We examined a 32-year-old Japanese man who was clinically diagnosed with gastric cancer, type 4, and histopathologically diagnosed with mucinous and poorly differentiated adenocarcinoma (mucinous > poorly) of the stomach.
  • We successfully established and characterized a cell line (designated as IGSK-2) derived from the ascitic fluid of the patient with recurrent and cisplatin-resistant carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secretion. Ascitic Fluid / cytology. Cell Line, Tumor. Chorionic Gonadotropin / secretion. Somatostatin / secretion. Stomach Neoplasms / pathology. Stomach Neoplasms / secretion

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1989 Dec 15;44(6):1100-3 [2606577.001]
  • [Cites] Virchows Arch. 2001 May;438(5):451-6 [11407472.001]
  • [Cites] Jpn J Cancer Res. 1996 Feb;87(2):153-60 [8609064.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2773-80 [2158397.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Mar;19(1):113-20 [10840945.001]
  • [Cites] BMC Cancer. 2006 Mar 14;6:57 [16536871.001]
  • [Cites] Hum Cell. 1989 Sep;2(3):307-9 [2562403.001]
  • [Cites] Hum Cell. 1999 Mar;12(1):3-10 [10457900.001]
  • [Cites] Int J Cell Cloning. 1987 Jul;5(4):322-34 [3497992.001]
  • [Cites] Jpn J Surg. 1988 Jul;18(4):438-46 [3172586.001]
  • [Cites] Gastroenterol Jpn. 1989 Apr;24(2):219 [2744340.001]
  • [Cites] Int J Oncol. 2000 May;16(5):893-8 [10762624.001]
  • (PMID = 17547719.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Chorionic Gonadotropin; 0H43101T0J / irinotecan; 51110-01-1 / Somatostatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


73. Hatzifoti C, Roussel Y, Harris AG, Wren BW, Morrow JW, Bajaj-Elliott M: Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. Helicobacter; 2006 Apr;11(2):113-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Helicobacter pylori is recognized as a major risk factor for recurrent gastroduodenal inflammatory diseases and gastric adenocarcinoma.
  • The antigenic potential of its urease enzyme, a critical virulence factor required for colonization of the gastric mucosa, has been demonstrated in animal and human studies.
  • Increase in gastric beta-defensin 1 and marked induction in local IL-10 : IFN-gamma ratio up to 12 weeks post-immunization suggest a potential role for local innate immune responses in protection at the site of infection.
  • Our studies suggest that local innate immune responses may play a greater role than previously supposed in limiting H. pylori colonization in the gastric mucosa.
  • [MeSH-minor] Animals. Bacterial Proteins / genetics. Bacterial Proteins / immunology. Cell Proliferation. Colony Count, Microbial. Cytokines / biosynthesis. Cytokines / genetics. DNA, Bacterial / analysis. Disease Models, Animal. Enzyme-Linked Immunosorbent Assay. Gastric Mucosa / immunology. Gene Expression. Immunity, Innate. Lymphocytes / immunology. Mice. Mice, Inbred C57BL. RNA / analysis. Reverse Transcriptase Polymerase Chain Reaction. Spleen / immunology. beta-Defensins / biosynthesis. beta-Defensins / genetics

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Helicobacter. 2006 Dec;11(6):513-6 [17083371.001]
  • (PMID = 16579841.001).
  • [ISSN] 1083-4389
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Bacterial Vaccines; 0 / Cytokines; 0 / DNA, Bacterial; 0 / Vaccines, DNA; 0 / beta-Defensins; 63231-63-0 / RNA; EC 3.5.1.5 / Urease
  •  go-up   go-down


74. Qiu MZ, Li ZH, Zhou ZW, Li YH, Wang ZQ, Wang FH, Huang P, Aziz F, Wang DY, Xu RH: Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma. J Transl Med; 2010;8:107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma.
  • BACKGROUND: The existence of circulating tumor cells (CTCs) in peripheral blood as an indicator of tumor recurrence has not been clearly established, particularly for gastric cancer patients.
  • We conducted a retrospective analysis of the relationship between CTCs in peripheral blood at initial diagnosis and clinicopathologic findings in patients with gastric carcinoma.
  • METHODS: Blood samples were obtained from 123 gastric carcinoma patients at initial diagnosis. mRNA was extracted and amplified for carcinoembryonic antigen (CEA) mRNA detection using real-time RT-PCR.
  • Recurrent disease was found in 44 of 123 cases (35.8%), and 25 of these (56.8%) were positive for CEA mRNA.
  • CONCLUSIONS: CEA mRNA copy number in peripheral blood at initial diagnosis was significantly associated with disease recurrence in gastric adenocarcinoma patients.
  • Real-time RT-PCR detection of CEA mRNA levels at initial diagnosis appears to be a promising predictor for disease recurrence in gastric adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoembryonic Antigen / genetics. RNA, Messenger / blood. Reverse Transcriptase Polymerase Chain Reaction / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Jan;16(1):128-32 [9440733.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3106-10 [9242433.001]
  • [Cites] Surg Today. 1998;28(7):701-6 [9697262.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1368-72 [9823981.001]
  • [Cites] Surg Today. 2005;35(6):436-41 [15912289.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Apr;132(4):248-56 [16320073.001]
  • [Cites] Trends Mol Med. 2006 Mar;12(3):130-9 [16488189.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5972-7 [17062668.001]
  • [Cites] Gastric Cancer. 2006;9(4):308-14 [17235634.001]
  • [Cites] J Surg Res. 2008 Aug;148(2):205-9 [17936797.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):153-9 [19050704.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1432-9 [10735890.001]
  • [Cites] Jpn J Cancer Res. 2000 Sep;91(9):918-24 [11011120.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):85-9 [11146784.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):189-94 [11176124.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1647-53 [11410502.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):17-20 [11438448.001]
  • [Cites] Lab Invest. 2001 Oct;81(10):1351-61 [11598148.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4080-5 [11751505.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):548-53 [11802221.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):195-203 [12065095.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2073-84 [12114406.001]
  • [Cites] Int J Mol Med. 2003 Feb;11(2):217-21 [12525881.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1091-4 [12671691.001]
  • [Cites] Trends Mol Med. 2003 May;9(5):189-95 [12763523.001]
  • [Cites] Diagn Mol Pathol. 2003 Jun;12(2):88-95 [12766613.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):219-27 [14639606.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):531-7 [14760074.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):448-56 [15170447.001]
  • [Cites] Clin Oncol. 1984 Dec;10(4):325-32 [6210169.001]
  • [Cites] Eur J Cancer. 1991;27(11):1461-5 [1720636.001]
  • [Cites] Lancet. 1992 Sep 19;340(8821):685-9 [1381801.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):725-9 [7512130.001]
  • [Cites] J Invest Dermatol. 1997 Feb;108(2):166-9 [9008229.001]
  • [Cites] Gut. 1996 Nov;39(5):717-21 [9014772.001]
  • [Cites] Gut. 1997 Apr;40(4):512-5 [9176080.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):64-8 [9660027.001]
  • (PMID = 21040522.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / DNA Primers; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2989934
  •  go-up   go-down


75. Catalano F, Trecca A, Rodella L, Lombardo F, Tomezzoli A, Battista S, Silano M, Gaj F, de Manzoni G: The modern treatment of early gastric cancer: our experience in an Italian cohort. Surg Endosc; 2009 Jul;23(7):1581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The modern treatment of early gastric cancer: our experience in an Italian cohort.
  • BACKGROUND: Endoscopic submucosal dissection (ESD) has been developed as treatment for early gastric cancer (EGC) by Japanese authors.
  • METHODS: Forty-five patients for a total of 48 gastric lesions were enrolled in the study.
  • We define as curative treatment lateral and vertical margins of the resected specimens free of cancer and repeat endoscopic finding of no recurrent disease.
  • [MeSH-major] Adenocarcinoma / surgery. Gastroscopy / methods. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Cohort Studies. Coloring Agents. Dissection. Early Diagnosis. Equipment Design. Female. Gastric Mucosa / surgery. Gastroscopes. Humans. Indigo Carmine. Italy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. INDIGO .
  • Hazardous Substances Data Bank. Indigotindisulfonate sodium .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2010 Jun;24(6):1505 [20035354.001]
  • [CommentIn] Surg Endosc. 2010 Jun;24(6):1507-9 [20044771.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2001 Jul;11(3):511-8 [11778752.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):877-83 [17140890.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):58-62 [8454147.001]
  • [Cites] Gastric Cancer. 2006;9(4):262-70 [17235627.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):596-601 [16564858.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):1001-6 [17058165.001]
  • [Cites] Jpn J Clin Oncol. 2001 Oct;31(10):495-9 [11696619.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3174-8 [8242540.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] Surgery. 1999 Feb;125(2):148-54 [10026747.001]
  • [Cites] Tumori. 2007 Jul-Aug;93(4):367-73 [17899867.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):788-801 [15326574.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):390-6 [11868015.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):987-90 [17058162.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):221-6 [11293753.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):776-82 [16650537.001]
  • [Cites] Gastric Cancer. 2000 Dec;3(4):219-225 [11984739.001]
  • [Cites] BMJ. 1993 Sep 4;307(6904):591-6 [8401015.001]
  • [Cites] Gastrointest Endosc. 2002 Apr;55(4):576-81 [11923778.001]
  • [Cites] Br J Surg. 1987 Jul;74(7):618-9 [3620874.001]
  • [Cites] Gastric Cancer. 2007;10(1):1-11 [17334711.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):602-6 [8616749.001]
  • [Cites] J Gastroenterol. 2006 Oct;41(10):929-42 [17096062.001]
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):819-22 [10570343.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1146-53 [17576611.001]
  • [Cites] Gastric Cancer. 2006;9(1):3-8 [16557429.001]
  • [Cites] Gastrointest Endosc. 2003 Apr;57(4):567-79 [12665775.001]
  • [Cites] Endoscopy. 1995 Jan;27(1):27-31 [7601031.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):212-8 [16860071.001]
  • (PMID = 19263148.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coloring Agents; D3741U8K7L / Indigo Carmine
  •  go-up   go-down


76. Kawaoka T, Matsukuma S, Nagashima A, Hiraki S, Fukuda S: [A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2415-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy].
  • He had a history of laparoscopic-assisted distal gastrectomy for gastric cancer about 11 months ago.
  • The stage was IB and pathological examination was poorly differentiated adenocarcinoma.
  • The pathological diagnosis was recurrent of gastric cancer.
  • It is important to understand that gastric cancer diagnosed poorly differentiated adenocarcinoma pathologically sometimes occurs duodenal invasion and obstructive jaundice.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Duodenum / pathology. Jaundice, Obstructive / etiology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224591.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; Familial duodenal atresia
  •  go-up   go-down


77. Kawaguchi M, Asada Y, Terada T, Takehara A, Munemoto Y, Fujisawa K, Mitsui T, Iida Y, Miura S, Sudo Y: Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor. Int J Clin Oncol; 2010 Apr;15(2):191-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor.
  • His family history included a sister with gastric cancer.
  • CT scan and fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrated gastric cancer and its metastatic lymph nodes.
  • G-CSF-producing tumor is a rare but aggressive disease, particularly as recurrent tumor.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Granulocyte Colony-Stimulating Factor / metabolism. Liver Neoplasms / secondary. Peritoneal Neoplasms / secondary. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2005;8(3):173-7 [16086120.001]
  • [Cites] Histol Histopathol. 2002 Oct;17 (4):1005-16 [12371127.001]
  • [Cites] Ann Nucl Med. 2008 Aug;22(7):635-9 [18756367.001]
  • [Cites] Surg Today. 2008;38(5):453-7 [18560971.001]
  • [Cites] Jpn J Clin Oncol. 2007 Oct;37(10):793-6 [17720735.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Ann Pharmacother. 2002 Nov;36(11):1796-9 [12398579.001]
  • [Cites] Gastric Cancer. 2005;8(3):198-201 [16086124.001]
  • [Cites] Ann N Y Acad Sci. 1974;230:212-8 [4522870.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):782-8 [3874682.001]
  • (PMID = 20179985.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  • [Number-of-references] 15
  •  go-up   go-down


78. Coumaros D, Tsesmeli N: Active gastrointestinal bleeding: use of hemostatic forceps beyond endoscopic submucosal dissection. World J Gastroenterol; 2010 Apr 28;16(16):2061-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten days after combined endotherapy, he had recurrent bleeding from two minimal lesions in the same location.
  • A 61-year-old woman underwent endoscopic mucosal resection of superficial gastric adenocarcinoma, which was complicated with immediate bleeding.

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2006 Feb;63(2):243-9 [16427929.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):178-83 [16377346.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):980-6 [17058161.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):991-5 [17058163.001]
  • [Cites] Endoscopy. 2007 May;39(5):418-22 [17516348.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):100-7 [17591481.001]
  • [Cites] Gastrointest Endosc. 2007 Aug;66(2):343-54 [17643711.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1610-6 [17403076.001]
  • [Cites] Gastrointest Endosc. 2007 Oct;66(4):831-5 [17905030.001]
  • [Cites] Gastrointest Endosc. 2007 Nov;66(5):966-73 [17524403.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E156 [16775794.001]
  • [Cites] Med Clin North Am. 2008 May;92(3):511-50, vii-viii [18387375.001]
  • [Cites] Endoscopy. 2009 Apr;41(4):299-303 [19340731.001]
  • [Cites] Endoscopy. 2009 Apr;41(4):340-5 [19340739.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 May;7(5):e22 [19022399.001]
  • [Cites] Endoscopy. 2009 Aug;41(8):679-83 [19670135.001]
  • [Cites] Endoscopy. 2009 Sep;41(9):758-61 [19746316.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jul;3(7 Suppl 1):S74-6 [16013004.001]
  • [Cites] Endoscopy. 2005 Aug;37(8):764-8 [16032498.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):781-2; discussion 782 [16246697.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005415 [17054257.001]
  • (PMID = 20419846.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hemostatics
  • [Other-IDs] NLM/ PMC2860086
  •  go-up   go-down


79. Suenaga M, Mizunuma N, Chin K, Matsusaka S, Shinozaki E, Oya M, Ueno M, Yamaguchi T, Muto T, Konishi F, Hatake K: Chemotherapy for small-bowel Adenocarcinoma at a single institution. Surg Today; 2009;39(1):27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for small-bowel Adenocarcinoma at a single institution.
  • PURPOSE: Small-bowel adenocarcinoma (SBA) is rare.
  • At Cancer Institute Hospital (CIH), the chemotherapy regimen used for colorectal cancer is initially used for patients with SBA, followed by that used for gastric cancer.
  • METHODS: Patients with advanced or recurrent SBA who had been treated with chemotherapy in CIH were retrospectively analyzed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Am J Surg. 1978 Apr;135(4):601-3 [637208.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):350-4 [3565678.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Am J Surg. 1986 Jun;151(6):654-8 [2424326.001]
  • [Cites] Surg Today. 1997;27(1):60-3 [9035302.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):116-28 [3285475.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):316-22 [15333683.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] Ann Surg Oncol. 1994 Jul;1(4):290-5 [7850527.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • (PMID = 19132464.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


80. Jung JY, Kwon JH, Kim JH, Song HH, Kim I, Lee KS, Kim HJ, Zang DY, Ahn JS, Lee JA, Park YI: Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer. Oncol Rep; 2009 Feb;21(2):523-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
  • Advanced or metastatic gastric cancer, which is one of the most common malignancies in Korea, is difficult to cure by surgery alone and generally requires combination chemotherapy.
  • Paclitaxel is active against gastric cancer and when combined with 5-fluorouracil/leucovorin and/or cisplatin is effective in the treatment of gastric cancer.
  • We attempted to determine the effect and safety with the combination of paclitaxel with split cisplatin and 5-fluorouracil/leucovorin in advanced or metastatic gastric cancer.
  • Patients with histologically-proven locally advanced/metastatic or recurrent gastric cancer with an ECOG performance status 0-2 were enrolled.
  • TPFL combination chemotherapy is effective and tolerable with acceptable toxicities in patients with advanced/metastatic, recurrent gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148531.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


81. Kanechorn Na Ayuthaya R, Patthamapasphong N, Sura T, Niumpradit N, Trachoo O: Ehlers-Danlos syndrome type IV with gastric adenocarcinoma. J Med Assoc Thai; 2008;91 Suppl 1:S166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ehlers-Danlos syndrome type IV with gastric adenocarcinoma.
  • Abdominal aortic aneurysm were detected with upper gastrointestinal hemorrhage, esophagogastroduodenoscopy showed diffuse gastric body swelling and erythema resulting in chronic gastritis.
  • Gastric biopsy was indicative of adenocarcinoma of the stomach and gastrectomy was done.
  • CONCLUSION: After gastrectomy, the patient became drowsy and unconscious from profuse recurrent cerebral hemorrhage and expired.
  • [MeSH-major] Adenocarcinoma / complications. Ehlers-Danlos Syndrome / etiology. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Ehlers-Danlos syndrome.
  • MedlinePlus Health Information. consumer health - Ehlers-Danlos Syndrome.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672610.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / COL3A1 protein, human; 0 / Collagen Type III
  •  go-up   go-down


82. Vemulakonda VM, Lendvay TS, Shnorhavorian M, Joyner BD, Kaplan H, Mitchell ME, Grady RW: Metastatic adenocarcinoma after augmentation gastrocystoplasty. J Urol; 2008 Mar;179(3):1094-6; discussion 1097
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma after augmentation gastrocystoplasty.
  • To define better the risk of malignancy associated with gastric augmentation and the appropriate surveillance protocol for these patients, we describe our experience in 2 patients with metastatic adenocarcinoma following gastrocystoplasty.
  • Neither patient had a history of gross hematuria, recurrent urinary tract infections or pain before initial presentation.
  • CONCLUSIONS: Although the risk of bladder cancer is low after gastric augmentation, the effects may be life threatening.
  • [MeSH-major] Adenocarcinoma / etiology. Stomach Neoplasms / etiology. Urinary Bladder Neoplasms / etiology. Urologic Surgical Procedures / adverse effects

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206936.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Tomiyama K, Takahashi M, Fujii T, Kunisue H, Kanaya Y, Maruyama S, Yokoyama N, Shimizu N, Soda M: A rare case of recurrent alpha-fetoprotein-producing gastric cancer without re-elevation of serum AFP. J Int Med Res; 2006 Jan-Feb;34(1):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of recurrent alpha-fetoprotein-producing gastric cancer without re-elevation of serum AFP.
  • We report an extremely rare case of recurrent alpha-fetoprotein (AFP)-producing gastric cancer without re-elevation of serum AFP.
  • The patient was a 78-year-old woman with AFP-producing gastric cancer, a rare type of gastric adenocarcinoma.
  • A Borrmann III gastric tumour was surgically resected and AFP-producing gastric cancer was diagnosed based on high levels of serum AFP (705.44 ng/ml) and immunohistochemical examination of the tumour.
  • [MeSH-major] Adenocarcinoma / metabolism. Stomach Neoplasms / metabolism. alpha-Fetoproteins / analysis. alpha-Fetoproteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604831.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


84. Matsuyama T, Izumi Y, Ito T, Tokita H, Iwao Y, Nishida K, Sakamoto K, Hosokawa T, Chika N, Kakimoto M, Park S, Yoshimura T, Koshiishi H, Okamura T: [Resection of local recurrent gastric cancer following total gastrectomy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2445-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resection of local recurrent gastric cancer following total gastrectomy].
  • We report a case of patient who underwent resection for local recurrent gastric cancer at the anastomotic site curatively.
  • The patient was a 72 years old male with a history of undergoing total gastrectomy for gastric cancer located at the gastric cardia in February 2005.
  • The histological findings of the resected tumor showed a Type 3 advanced gastric cancer invaded into subserosa in the cardia of the stomach with positive lymphatic and venous invasion and lymph node metastasis.
  • The histological diagnosis was moderately differentiated tubular adenocarcinoma.
  • Endoscopy, 4 years after the first operation, showed a recurrent tumor at the site of esophago-jejunal anastomosis.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Neoplasm Recurrence, Local / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224601.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


85. Nitti D, Marchet A, Mammano E, Ambrosi A, Belluco C, Mencarelli R, Maino M, Marconato G, Farinati F, Lise M: Extended lymphadenectomy (D2) in patients with early gastric cancer. Eur J Surg Oncol; 2005 Oct;31(8):875-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended lymphadenectomy (D2) in patients with early gastric cancer.
  • METHODS: A review was made of our prospective gastric database from January 1980 to December 2001.
  • Of 527 patients with primary gastric adenocarcinoma, 119 with EGC underwent potentially curative resection (R0) with D2 lymphadenectomy.
  • During a median follow-up of 90 months, five of the eight patients with level 2 metastases died of recurrent disease and three were alive.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051460.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


86. Tachibana M, Hirahara N, Kinugasa S, Yoshimura H: Clinicopathologic features of superficial esophageal cancer: results of consecutive 100 patients. Ann Surg Oncol; 2008 Jan;15(1):104-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety-one patients (91%) were diagnosed to have the lesions by endoscopy at the time of screening for gastric problems, and only nine were detected by gastrointestinal series.
  • Five of 49 patients with submucosal cancer died of recurrent disease, and 4 of these developed regional nodal recurrence around the bilateral laryngeal recurrent nerves.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891442.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Lee SY, Lee JH, Hwang NC, Kim YH, Rhee PL, Kim JJ, Paik SW, Rhee JC, Sohn TS, Kim S: The role of follow-up endoscopy after total gastrectomy for gastric cancer. Eur J Surg Oncol; 2005 Apr;31(3):265-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of follow-up endoscopy after total gastrectomy for gastric cancer.
  • BACKGROUND: Follow-up endoscopy after total gastrectomy for gastric cancer is commonly performed without there being any definite evidence of clinical relevance.
  • Therefore, we investigated the role of the upper endoscopic examinations after total gastrectomy for gastric cancer.
  • METHODS: The medical records of 212 early gastric cancer (EGC) patients and 622 advanced gastric cancer (AGC) patients who underwent follow-up endoscopic examination after total gastrectomy between 1994 and 2001 were reviewed.
  • CONCLUSION: Follow-up endoscopy after total gastrectomy for gastric cancer is useful in detecting complications and tumour recurrence.
  • However, this procedure has a limited role in the clinical management and overall survival for patients with recurrent gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Endoscopy, Gastrointestinal. Gastrectomy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780561.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Shibata N, Eto TA, Asada T, Takaya T, Tanaka S, Shimayama T, Imada S, Futami S, Hidaka H, Chijiiwa K: [A case of recurrent gastric cancer during adjuvant chemotherapy with S-1, treated by S-1 combination chemotherapy]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1745-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent gastric cancer during adjuvant chemotherapy with S-1, treated by S-1 combination chemotherapy].
  • A 59-year-old man was admitted to our hospital for the treatment of gastric cancer with synchronous and multiple metastatic liver tumors.
  • Pathological study of both the resected specimens showed moderately differentiated adenocarcinoma.
  • However, CT scans showed recurrent multiple liver tumors after 4 courses of treatment with S-1.
  • This case suggests that after failure of S-1 therapy, S-1 combination chemotherapy might be an effective treatment for recurrent gastric cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838040.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


89. Takashima A, Shirao K, Hirashima Y, Takahari D, Okita NT, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y: Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. J Cancer Res Clin Oncol; 2010 Feb;136(2):243-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
  • PURPOSE: Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen.
  • RESULTS: From July 1999 to January 2007, 1,365 patients with unresectable or recurrent AGC received first-line CTx at the National Cancer Center Hospital in Tokyo, Japan.
  • Nineteen patients (86%) had histologically diffuse-type adenocarcinoma and 18 (82%) had bone metastasis.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disseminated Intravascular Coagulation / etiology. Stomach Neoplasms / complications. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fukuoka Igaku Zasshi. 1989 Oct;80(10):477-81 [2559010.001]
  • [Cites] Thromb Haemost. 2001 Sep;86(3):828-33 [11583315.001]
  • [Cites] Oncology. 1995 Nov-Dec;52(6):505-8 [7478440.001]
  • [Cites] Am J Hematol. 2000 Nov;65(3):215-22 [11074538.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] N Engl J Med. 1999 Aug 19;341(8):586-92 [10451465.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1293-7 [18505068.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jun;38(6):432-7 [18515821.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1277-9 [8067696.001]
  • [Cites] Thromb Haemost. 2003 Apr;89(4):660-5 [12669120.001]
  • [Cites] Thromb Diath Haemorrh. 1975 Sep 30;34(1):181-93 [171794.001]
  • [Cites] Science. 1979 Sep 14;205(4411):1135-7 [472732.001]
  • [Cites] Gastric Cancer. 2000 Aug 4;3(1):19-23 [11984704.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):316-22 [15333683.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Oct;77(10):5663-7 [6160578.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):52-56 [11957071.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):853-5 [17214103.001]
  • [Cites] Jpn J Clin Oncol. 2000 Mar;30(3):122-5 [10798538.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):960-9 [8164048.001]
  • [Cites] Gastric Cancer. 2001;4(4):212-8 [11846065.001]
  • [Cites] Am J Clin Oncol. 1998 Oct;21(5):452-7 [9781598.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1997 Mar;59(3):204-9 [9198298.001]
  • (PMID = 19727819.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


90. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res; 2006 Jun 1;12(11 Pt 1):3402-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
  • PURPOSE: To evaluate the efficacy and toxicity of docetaxel in combination with a novel oral 5-fluorouracil analogue S-1 for patients with advanced or recurrent gastric cancer.
  • EXPERIMENTAL DESIGN: Patients with advanced or recurrent adenocarcinoma of the stomach and up to one previous chemotherapy regimen were treated with i.v. docetaxel 40 mg/m2 on day 1 and oral S-1 80 mg/m2/d on days 1 to 14 every 3 weeks.
  • CONCLUSION: Docetaxel/S-1 combination is highly active and well tolerated in advanced or recurrent gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Oxonic Acid / administration & dosage. Stomach Neoplasms / drug therapy. Taxoids / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740764.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


91. Fujiyoshi Y, Kuhara H, Eimoto T: Composite glandular-endocrine cell carcinoma of the stomach. Report of two cases with goblet cell carcinoid component. Pathol Res Pract; 2005;200(11-12):823-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Composite glandular-endocrine cell carcinoma (CGECC) is recognized as a special type of gastric tumor composed of ordinary adenocarcinoma and neuroendocrine tumors.
  • We report on two gastric CGECCs with a GCC component, analyzing the histologic components by immunohistochemistry.
  • However, the resected tumors consisted of three components: signet-ring cell carcinoma, GCC, and glandular adenocarcinoma.
  • Both patients are well, with no recurrent tumor for about 10 years of follow-up.
  • CGECC with a GCC component may have been confused with conventional adenocarcinoma with signet-ring cells.


92. Gwon DI: Percutaneous transhepatic placement of covered, self-expandable nitinol stent for the relief of afferent loop syndrome: report of two cases. J Vasc Interv Radiol; 2007 Jan;18(1 Pt 1):157-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The author reports successful outcomes after percutaneous transhepatic placement of covered, self-expandable nitinol stents in two patients who had afferent loop syndrome caused by recurrent gastric carcinoma.
  • In each patient, enhanced abdominal computed tomography showed marked dilation of the jejunal limb and intrahepatic bile ducts incident to recurrent gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Afferent Loop Syndrome / therapy. Carcinoma, Signet Ring Cell / complications. Prosthesis Implantation / methods. Stents. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296719.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alloys; 52013-44-2 / nitinol
  •  go-up   go-down


93. Bar-Sela G, Tsalic M, Steiner M, Wollner M, Haim N: Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma. Anticancer Res; 2009 May;29(5):1853-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma.
  • BACKGROUND: The gold standard of adjuvant treatment after surgical resection of adenocarcinoma of the stomach or gastroesophageal junction (GEJ) is chemoradiotherapy.
  • We retrospectively evaluated chemotherapy without radiotherapy in stomach and GEJ adenocarcinoma, using a combination of etoposide, adriamycin and cisplatin (modified EAP).
  • PATIENTS AND METHODS: Sixty-five patients with completely resected gastric or GEJ adenocarcinoma and positive regional lymph nodes were treated with modified EAP over an 8-year period.
  • RESULTS: Recurrent disease was diagnosed in 38/58 (69%) patients evaluable for analysis.
  • Seventeen (26%) patients are alive for a median of 7+ years, with no evidence of recurrent disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Chemotherapy, Adjuvant. Neoplasm Recurrence, Local. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443416.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


94. Baba E, Fujishima H, Kusaba H, Esaki T, Ariyama H, Kato K, Tanaka R, Mitsugi K, Shibata Y, Harada M, Nakano S: Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer. Anticancer Res; 2009 May;29(5):1727-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
  • The combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) has been reported to be active against metastatic gastric cancer (MGC) and great synergy has been shown in vivo and in vitro when 5-FU precedes CDDP.
  • Patients with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, ECOG performance status less than 3 and adequate organ functions were eligible for the study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Metastasis / drug therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443394.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


95. Qureshi AU, Iqbal M, Gondal KM: Transhiatal esophageal surgery for malignancy--a 7-year experience at a tertiary care hospital. J Coll Physicians Surg Pak; 2009 Jul;19(7):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All underwent transhiatal esophagectomy and gastric tube or colon was used as the conduit to restore continuity.
  • Postoperative complications included pneumothorax 16.7%, pulmonary complication (16.7%), anastomotic leakage (9.5%), wound infection (3.4%), recurrent laryngeal nerve injury (4.8%) and stricture formation (4.8%).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19576147.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


96. Yannopoulos P, Theodoridis P, Manes K: Esophagectomy without thoracotomy: 25 years of experience over 750 patients. Langenbecks Arch Surg; 2009 Jul;394(4):611-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stomach was our esophageal substitute of first choice with the colon and jejunum being acceptable alternatives in patients with prior gastric surgery and those necessitating synchronous gastrectomy for cancer invasion.
  • A gastric tube was used as an esophageal substitute in 624 patients (83.2%), the whole stomach in 70 (9.4%), the colon in 43 (5.73%), and a jejunal loop in 13 (1.73%).
  • Major complications included atelectasis or pneumonia (4.8%), pleural effusion (22.7%), myocardial infarction (0.5%), recurrent laryngeal nerve paralysis (1.33%), and three tracheal lacerations (0.4%).

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Feb;25(2):196-203 [11338022.001]
  • [Cites] Ann Surg. 2007 Sep;246(3):363-72; discussion 372-4 [17717440.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1918-24; discussion 1924-5 [11789772.001]
  • [Cites] Am J Surg. 2002 Feb;183(2):162-7 [11918882.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Apr;15(2):197-209 [12838490.001]
  • [Cites] Dis Esophagus. 2003;16(3):243-5 [14641318.001]
  • [Cites] Arch Surg. 2004 Jun;139(6):627-31; discussion 631-3 [15197089.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1170-6; discussion 1170-6 [15464465.001]
  • [Cites] Br J Surg. 1975 Aug;62(8):601-4 [1174797.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Nov;76(5):643-54 [703369.001]
  • [Cites] Eur J Cardiothorac Surg. 1989;3(5):419-23; discussion 424 [2635923.001]
  • [Cites] Aust N Z J Surg. 1991 May;61(5):366-9 [2025191.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • [Cites] J Surg Oncol. 1994 Nov;57(3):157-63 [7967604.001]
  • [Cites] Chest Surg Clin N Am. 1997 Aug;7(3):601-10; discussion 611-2 [9246405.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Dec;114(6):948-55; discussion 955-6 [9434690.001]
  • [Cites] Surgery. 1999 Feb;125(2):142-7 [10026746.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):392-400; discussion 400-3 [10493486.001]
  • [Cites] Surg Clin North Am. 2005 Jun;85(3):593-610 [15927654.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • (PMID = 19350267.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2687514
  •  go-up   go-down


97. Lin CY, Jwo SC, Lin CC: Primary testicular actinomycosis mimicking metastatic tumor. Int J Urol; 2005 May;12(5):519-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a rare case of right primary testicular actinomycosis presenting as multiple testicular lesions mimicking a metastatic tumor in a 71-year-old patient with gastric adenocarcinoma.
  • The patient had not received any further antibiotic prescription and there was no recurrent or other site involvement after orchiectomy.
  • [MeSH-minor] Actinomyces / isolation & purification. Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Aged. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Neoplasm Metastasis / diagnosis. Orchiectomy. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis. Testis / microbiology. Testis / pathology. Testis / ultrasonography

  • Genetic Alliance. consumer health - Anaerobic Actinomyces Infection.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948759.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


98. Huang KH, Chen JH, Wu CW, Lo SS, Hsieh MC, Li AF, Lui WY: Factors affecting recurrence in node-negative advanced gastric cancer. J Gastroenterol Hepatol; 2009 Sep;24(9):1522-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting recurrence in node-negative advanced gastric cancer.
  • BACKGROUND AND AIM: Prognostic factors of lymph node-negative gastric adenocarcinoma after curative resection have been discussed.
  • Recurrent pattern of advanced lymph node-negative gastric cancer after curative resection has rarely been described.
  • METHODS: Recurrent sites and correlated clinicopathological factors of 372 patients with lymph node-negative advanced gastric adenocarcinoma that underwent R0 resection from 1988 to 2005 were analyzed.
  • Recurrent rates according to site of recurrence were 26 peritoneal seeding (51.0%), 26 locoregional (51.0%), 17 hematogenous (33.3%), and 4 lymph node metastasis (7.8%).
  • CONCLUSION: Node-negative advanced gastric cancer has more peritoneal seeding and locoregional recurrence.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Gastrectomy. Hematologic Neoplasms / pathology. Neoplasm Recurrence, Local. Neoplasm Seeding. Stomach Neoplasms / secondary. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol Hepatol. 2009 Sep;24(9):1478-9 [19743992.001]
  • (PMID = 19467143.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


99. Pérez-Roldán F, González-Carro P, Legaz-Huidobro M, Oruezabal-Moreno M, Soto Fernández S, Roncero García-Escribano O, de Pedro Esteban A, Ruiz-Carrillo F, Seoane-González J: Esophagoenteral stents in patients with recurrent gastric adenocarcinoma. Rev Esp Enferm Dig; 2006 May;98(5):341-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophagoenteral stents in patients with recurrent gastric adenocarcinoma.
  • One of the problems that can appear in patients with total gastrectomy for adenocarcinoma with esophagoenteral anastomosis is the appearance of a stenosis of the anastomosis.
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma / therapy. Esophagus / surgery. Stents. Stomach / surgery. Stomach Neoplasms / surgery. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Anastomosis, Roux-en-Y. Anastomosis, Surgical. Female. Gastrectomy. Gastric Bypass. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Palliative Care

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944994.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


100. Tew WP, Kelsen DP, Ilson DH: Targeted therapies for esophageal cancer. Oncologist; 2005 Sep;10(8):590-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fact, gastric and esophageal cancers together accounted for nearly 1.3 million new cases and 980,000 deaths worldwide in 2000-more than lung, breast, or colorectal cancer.
  • Although esophageal squamous cell carcinoma cases have steadily declined, the incidence of gastroesophageal junction adenocarcinoma has increased 4%-10% per year among U.S. men since 1976, more rapidly than for any other cancer type, and parallels rises in population trends in obesity and reflux disease.
  • (c) high risk for recurrent disease after esophagectomy or definitive chemoradiotherapy;.
  • This review focuses on novel targeted treatments in development for esophageal squamous cell carcinoma and distal esophageal and gastroesophageal junction adenocarcinoma.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177283.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 128
  •  go-up   go-down






Advertisement